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This work covers two projects related to protein structure and function. The first focuses on 
studies of chloroplast signal recognition particle 43 (cpSRP43), its interaction with 
substrate (the light-harvesting, chlorophyll-binding proteins, or LHCP), the role of 
conformational change in its activity, and the use of cpSRP43 as a tool for handling 
nonnative proteins. This work utilizes a variety of biochemical and biophysical approaches 
including light scattering and electron paramagnetic resonance to probe the structure-
function relationship of cpSRP43. The second project entails the study of the C-C bond 
formation mechanism of nitrogenase, a biological nitrogen fixer found in soil 
microorganisms. Together these projects make for an interesting story of the medicinal and 
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Chaperone. Protein that assists in folding/unfolding or assembly/disassembly of other 
proteins (e.g. prevention of aggregation) 
Enzyme. Protein that lowers the activation energy barrier for a chemical reaction. 
Conformational change. Change in structure of protein. 
cpSRP43. Chloroplast signal recognition particle 43 (chaperone). 
cpSRP54. Chloroplast signal recognition particle 54 (conformational regulator). 
 
LHCP. Light-harvesting, chlorophyll-binding proteins. 
 
Alb3. Translocase in thylakoid membrane. 
 
Nitrogenase. Nitrogen-fixing enzyme found in soil microorganisms. 
 
Technique Terminology 
NEM-Alkylation. N-ethylmaleimide (NEM) alkylation involves studying protein 
complexes by adding an alkylation site on a protein and then incubating with an alkylating 
agent such as NEM. 
 
Light scattering assay. Measures turbidity (cloudiness) of solution to detect aggregates. 
 
Fluorescence Anisotropy. Measures binding of fluorescently-tagged peptide to a protein 
of interest. 
 
HDX-MS. Hydrogen-deuterium exchange mass spectrometry measures local mobility 
through exchange of hydrogen (water) for deuterium (D2O). 
 
EPR. Electron Paramagnetic Resonance, uses a tagged protein (typically with an MTSSL 
tag) with unpaired electron to study local mobility. 
 
Western Blot. A tagged protein is recognized by an antibody (such as anti-His or anti-
FLAG) that is then recognized by a secondary antibody (such as anti-mouse or anti-rabbit) 
which is detected by developing a film. 
 





I n t r o d u c t i o n  
UNDERSTANDING PROTEIN TRANSPORT AND CATALYSIS IN THE 
BIOLOGICAL WORLD 
This thesis is broken down into two sections, each with a unique, interdisciplinary approach at 
understanding processes in the biological world as a platform for engineering useful tools. The first 
section of this thesis focuses on chaperones and protein transport and is broken down into four 
chapters: the first chapter focuses on substrate-chaperone interaction with a membrane protein, the 
second on the cycle of substrate capture and release, the third on conformational transitions that 
drive this cycle, and the fourth on applying this small, ATP-independent chaperone to the problem 
of membrane protein expression. The second section goes on to take a combined organic and 
biophysical approach to characterize a carbon-carbon bond formation reaction between nitrogenase 
and methyl isonitrile for industrial synthesis applications. This section then goes on to review 
nitrogenase substrate scope and assess the potential role of hydrazine as an intermediate in nitrogen 
reduction. Together these works showcase the usefulness and variety of macromolecular machines 





C h a p t e r  1  
A MEMBRANE PROTEIN CHAPERONE BINDS TO SUBSTRATE 
THROUGH TWO UNIQUE MODES 
Work published in: 
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Integral membrane proteins are prone to aggregation and misfolding in aqueous environments 
and therefore require binding by molecular chaperones during their biogenesis, targeting, and assembly. 
Chloroplast signal recognition particle 43 (cpSRP43) is an ATP-independent chaperone required for the 
biogenesis of the most abundant class of membrane proteins, the light-harvesting chlorophyll a/b-binding 
proteins (LHCPs). Previous work has shown that cpSRP43 specifically recognizes an L18 loop sequence, 
which is conserved among LHCP paralogs. However, how cpSRP43 protects the transmembrane domains 
(TMDs) of LHCP from aggregation has been unclear. In this work, alkylation-protection experiments 
identified the first two TMDs of Lhcb5, a member of the LHCP family, and their intervening loop as major 
sites of protection by cpSRP43. Site-directed mutagenesis identified a class of cpSRP43 mutants that bind 
tightly to the L18 sequence but are defective in chaperoning full-length LHCP.  These mutations mapped 
to hydrophobic surfaces on the bridging helix and the β-hairpins lining the ankyrin repeat motif (ARM) of 
cpSRP43, implying that these regions are potential sites for interaction with the client TMDs. Our results 
suggest a working model for client protein interactions involving this membrane protein chaperone. 
 
 
Proper protein folding and localization are critical for cellular protein homeostasis, which is acutely 
challenged by the post-translational targeting of integral membrane proteins. Before arrival at the target 
membrane, nascent membrane proteins are highly prone to aggregation in the cytosol and other aqueous cellular 
compartments. Thus, effective molecular chaperones or chaperone networks are required to minimize improper 
exposure of the transmembrane domains (TMDs) on newly synthesized membrane proteins and to maintain them 
in soluble, translocation-competent conformations. Many chaperone proteins are linked to membrane protein 
biogenesis, including SecB, Skp, and SurA that protect bacterial outer membrane proteins, and Hsp70 
homologues implicated in the import of mitochondrial and chloroplast proteins (1-6). 
The light-harvesting chlorophyll a/b-binding proteins (LHCP) comprise over 50% of the protein content 
on the thylakoid membrane of green plants (7) and form the most bundant family of membrane proteins on earth.  
LHCPs are nuclear-encoded, initially synthesized in the cytosol, and imported across the chloroplast envelope in 
a largely unfolded state (8). In the chloroplast stroma, LHCPs are protected in a soluble ‘transit complex’ by the 
chloroplast signal recognition particle (cpSRP), comprised of the cpSRP43 and cpSRP54 protein subunits (9-12). 
LHCPs are then delivered to the Alb3 translocase and inserted into the thylakoid membrane via interactions 
between the GTPase domains of cpSRP54 and its receptor cpFtsY (9, 13-16). Previous work showed that the 
cpSRP43 subunit binds tightly to and quantitatively prevents the aggregation of multiple members of the LHCP 
family, and that it is necessary and sufficient to chaperone LHCPs (17). Although the chaperone activity of 
cpSRP43 is allosterically regulated by additional components in the cpSRP pathway, such as cpSRP54 and Alb3 
(18-23), the simple composition of the cpSRP43-LHCP chaperone-client pair and the robustness of cpSRP43’s 
chaperone activity make this pair an excellent system to understand the interaction and regulation of membrane 
protein chaperones.   
A long-standing question about the cpSRP43-LHCP system is the mechanism by which the TMDs on the 
substrate proteins are protected by cpSRP43. The substrate-binding domain (SBD) of cpSRP43 is comprised of 
Ankyrin repeat motifs (ARMs), capped at the N-terminus by a chromodomain (CD1) and at the C-terminus by a 
bridging helix (BH) (24-26). Biochemical and crystallographic analyses showed that a conserved Tyr204 in the 
third ARM recognizes an FDPLGL motif in L18, a conserved 18-amino acid sequence between the second and 
third TMDs of LHCP (17, 24, 27-28). However, interaction with a soluble loop sequence is unlikely to be 
sufficient to protect LHCPs, which contain three TMDs, from aggregation. The ability of cpSRP43 to 
quantitatively prevent full-length LHCPs from aggregation is highly suggestive of additional interactions between 
cpSRP43 and the substrate TMDs. Nevertheless, deletion of individual TMDs in LHCP or replacement with the 
TMDs from unrelated membrane proteins did not severely disrupt the cpSRP43-LHCP interaction (28); this lack 
of specificity rendered the putative TMD interactions of cpSRP43 particularly challenging to demonstrate and 
identify. Although a crosslinking study identified three additional residues in TM3 of LHCP that can crosslink to 
cpSRP43 (29), the study was limited to TM3 and did not examine additional possible interaction with the 





rearrangements occur in the cpSRP43 SBD upon substrate binding (25), making it particularly challenging to 
define the interaction of this chaperone with the substrate TMDs.  
In this work, we used a combination of alkylation/protection and site-directed mutagenesis studies to 
understand the interaction between cpSRP43 and its client protein. The results completely defined the sites of 
LHCP that are protected by cpSRP43 upon their interaction, and identified a set of mutant cpSRP43s that are 
specifically disrupted in their ability to chaperone LHCP without affecting binding of the L18 motif.  These 
observations suggest potential TMD interaction sites on this membrane protein chaperone.  
 
RESULTS   
Mapping the interaction sites of cpSRP43 on Lhcb5 through alkylation/protection patterns. To define the sites 
on Lhcb5 involved in complex formation with cpSRP43, we tested the ability of cpSRP43 to protect individual 
residues in Lhcb5 from alkylation by N-ethylmaleimide (NEM). To this end, we purified a set of Lhcb5 variants in 
which single cysteines were engineered at every 5-10 residues across the entire sequence of Lhcb5 (30).  Lhcb5 is 
a close homologue of LHCP that strongly depends on the cpSRP pathway for its biogenesis, and previous work 
showed that Lhcb5 forms a tight complex with cpSRP43 with an apparent Kd value of ~10 nM; further, because 
Lhcb5 has only one native cysteine it was the ideal substrate to use for making single cysteine mutants (28). To 
ensure that all Lhcb5’s are bound by the chaperone, we tested the efficiency of complex formation between each 
single cysteine variant of Lhcb5 and cpSRP43 (Table 1), and cpSRP43•Lhcb5 complexes were assembled using 
concentrations of cpSRP43 that are saturating for each Lhcb5 mutant. Further, the correlation of % soluble 
substrate in light scattering and % translocation in membrane targeting (Figure 2G) indicates that real client-
chaperone complexes are being observed through these experiments. The previously identified FDPLGL 
interaction motif in the L18 sequence was not tested, as point mutations at any of these residues severely 
impaired complex formation with cpSRP43 (24, 28). The efficiency of NEM alkylation was quantified by  
intact mass spectrometry and provides a direct measure for the solvent accessibility of individual cysteine 
residues in Lhcb5 (30). Previous work showed that LHCPs are imported into the chloroplast and maintained by 
cpSRP in a largely unfolded state (13). All the engineered single cysteines in Lhcb5 denatured in 6M GdmCl were 
alkylated by NEM to >90% completion (30). Thus, comparison of the alkylation efficiency in the 
cpSRP43•Lhcb5 complex to that of chemically denatured Lhcb5 provides a measure for the degree to which 
individual residues in Lhcb5 are protected by interaction with cpSRP43.  The observed alkylation-protection 
pattern differs significantly from studies of Lhcb5 aggregation in aqueous buffer (30), particularly in TM1, the 
end of TM2, and the C-terminus, indicating that the alkylation-protection patterns reported here reflect complex 
formation and not client aggregation. Representative data for the complexes of two Lhcb5 variants, E156C and 
V135C, are shown in Figures 1A and 1B, respectively. Deconvolution and quantification of the m/z spectrum 
showed that for the E156C mutant of Lhcb5, a single alkylated species was present after a 10 minute alkylation 
reaction, indicating that this site was fully alkylated and thus relatively solvent exposed in the complex (Figure 
1A). By contrast, the m/z spectrum of the V135C mutant of Lhcb5 contained both the unalkylated and alkylated 
species (Figure 1B), indicating that this site was protected by cpSRP43 and likely involved in Lhcb5-cpSRP43 
interaction.  
 The results of the alkylation-protection experiments for all the Lhcb5 variants are summarized in Figure 1C. 
When the alkylation efficiencies at 10 minutes were mapped onto the sequence of Lhcb5 (Figure 1D), several 
patterns were observed. Residues 70–143, which span the first two TMDs of Lhcb5 and their intervening loop, 
were modestly to heavily protected, suggesting that they interact with cpSRP43 in the cpSRP43•Lhcb5 complex. 
Residues 190–200, which form the C-terminal part of TM3, were also protected, consistent with the results of a 
previous crosslinking study (30).  In contrast, residues in the N- and C-terminal portions of Lhcb5 were either 
highly accessible or modestly protected. In addition, residues in the loop connecting TM2 and TM3 of Lhcb5 
were relatively accessible, consistent with crystallographic analysis showing that the L18 peptide is bound at a 
solvent accessible site on the surface of cpSRP43 (29). Together, these results show that cpSRP43 contacts and 
protects its substrates at all three TMDs, with extensive interactions formed with TM1, TM2, their intervening 
loop, and the C-terminus of TM3.  
 
cpSRP43’s substrate binding domain is highly sensitive to point mutations. Previous work established that 
CD1, the ARMs, and the BH together form a structural and functional unit that comprises the SBD of cpSRP43 





solvent-exposed hydrophobic residues (Leu, Ile, Val, and Trp) in the SBD, as well as additional residues on the β-
hairpins of the ARMs and on the BH (highlighted in blue in Figure 2A). Each residue was mutated to cysteine in 
an otherwise cysteine-less cpSRP43 (C118A, C240S). Cysteine-less cpSRP43 is 5-fold reduced in binding and 
chaperoning LHCP compared to wildtype cpSRP43 because it is shifted to a less active conformation (25), but 
otherwise behaves analogously to wildtype cpSRP43.  
We tested each single cysteine mutant of cpSRP43 for  
its ability to bind and protect LHCP from aggregation using a well-established light scattering assay (Figure 2B 
and 2C). In this assay, LHCP denatured and solubilized in 8M urea was added to a solution containing either 
buffer, cysteine-less cpSRP43 (referred to as WT), or the mutant cpSRP43 of interest, and the turbidity of the 
solution was monitored in real time. In the absence of cpSRP43, LHCP aggregated extensively in aqueous 
solution (Figures 2B and 2C, green lines). The presence of 2.5 µM cysteine-less cpSRP43 prevented the 
aggregation of ~55% of LHCP (Figs. 2B and 2C, black lines); this cpSRP43 concentration thus provides the most 
sensitive condition to screen for mutant cpSRP43s defective in chaperone activity. Further, the results observed 
through this light scattering assay were mirrored by sedimentation experiments (Figure 2E) in which mutant 
cpSRP43s were incubated with LHCP in aqueous buffer and separated into pellet (aggregated) and soluble 
fractions. 
We found that single point mutations of a surprisingly large number of residues in the cpSRP43 SBD 
compromised its chaperone activity. Of the 33 single cysteine mutants tested, only 10 mutants exhibited 
chaperone activities within three-fold of that of cysteine-less cpSRP43 (Fig. 2B). Six mutants exhibited 3-5 fold 
reductions in the solubilization of LHCP compared to cysteine-less cpSRP43, and chaperone activity was 
undetectable for 17 mutants (Fig. 2C and 2D). The residues whose mutation induced modest or severe defects in 
chaperone activity span almost an entire surface of the cpSRP43 SBD (Figure 4). Thus, cpSRP43 is highly 
sensitive to conservative perturbations in its SBD. 
 
Two distinct classes of defective cpSRP43 SBD. mutants. The large number of surface residues that exhibit a 
mutational defect in substrate binding could arise from an extensive interaction surface of cpSRP43 with LHCP, 
or from perturbation of the global conformation of the SBD by these mutations. Recent NMR studies showed that 
the SBD of apo-cpSRP43 intrinsically samples active and inactive conformations with equal probability (25), 
supporting the possibility that the conformation of cpSRP43 could be particularly susceptible to mutations. To 
control for mutational effects on the global conformation of the SBD, we tested the ability of cpSRP43 mutants to 
bind the L18 recognition motif of LHCP. All of the chaperone-defective mutations examined here are located 
away from the crystallographically identified L18 binding site of cpSRP43 (Y204 highlighted in Figures 3D & E; 
24); thus, a defect in L18 binding caused by these mutations most likely arises from a global structural defect of 
the SBD, rather than disruption of a direct interaction with L18.   
The binding affinity of cpSRP43 for the L18 motif  was measured based on the cpSRP43-induced increase in the 
fluorescence anisotropy of a HiLyte-Fluor488-conjugated L11 peptide, which represents the minimal sequence in 
L18 required for high affinity binding to cpSRP43. LHCP’s L11 minimal binding motif was identified via a 
series of deletions in the L18 motif centered around the DPLG sequence, which has been shown to directly 
interact with cpSRP43 (24). We tested the ability of cpSRP43 to prevent aggregation and disassemble aggregates 
of each L18 truncation construct and the results are summarized in Supplementary Table 1. GSFDPLGLADD, or 
the L11 motif, was the minimal motif required for cpSRP43 to recognize and chaperone LHCP with comparable 
efficiency to wildtype LHCP. Representative equilibrium titrations for L11-cpSRP43 binding are shown in 
Figures 3A and B. The equilibrium dissociation constants (Kd) for L11 binding to WT and mutant cpSRP43’s, 
derived from the equilibrium titrations, are summarized in Table 2. The anisotropy change of L11 induced by a 
subsaturating concentration (0.19 µM) of each mutant cpSRP43 relative to that of WT cpSRP43 are summarized 
in Figure 3C.   
We found that mutation of a large number of residues affected the interaction of cpSRP43 with the L18 motif.  
Eight mutants bound the L11 peptide an order of magnitude more weakly than WT cpSRP43 (Kd ~ 0.8–3.5 µM; 
Figure 3B and Table 2, yellow), and three mutants exhibited ~100-fold weakened binding to L11 (Kd > 10 µM; 
Table 2, red).  In contrast, twelve mutant cpSRP43s bound the L11 peptide with Kd values within 5-fold of that of 
WT cpSRP43 (Kd  < 0.6 µM; Figure 3A and Table 2, green).  We defined these twelve mutants as Class I. 
Mutants in this class either bind L11 with similar affinity compared to WT cpSRP43 but are defective in 





account for their complete loss of chaperone activity towards LHCP.  Thus, Class I mutants specifically disrupt 
the ability of cpSRP43 to protect the TMDs of LHCP from aggregation. The remainder of the chaperone-
defective mutants are designated as Class II.  These mutants were substantially disrupted in interaction with the 
L18 motif, although the mutations are located at sites away from the vicinity of the L18 binding site; thus, these 
mutations disrupt L18 binding through an allosteric effect, by altering the conformation of the SBD.   
 
DISCUSSION  
cpSRP43 is a small, ATP-independent chaperone with a SBD comprised mostly of an ankyrin repeat motif. At a 
size of 25 kDa, the cpSRP43 SBD is able to effectively chaperone multi-pass membrane protein substrates 
comparable to its own size, providing an intriguing system to understand how a small protein scaffold interacts 
with and provides protection for large client proteins. Our previous understanding of the cpSRP43-LHCP 
interaction was limited to recognition of the L18 loop sequence in LHCP by cpSRP43-Tyr204 (17, 24, 27). In 
this work, the results of alkylation-protection experiments showed that LHCP is extensively protected in its 
complex with cpSRP43; the regions of protection span all three TMDs of LHCP as well as the loop between TM1 
and TM2, suggesting that these sites are either directly contacted by cpSRP43, or protected via intramolecular 
interactions induced by cpSRP43.  Furthermore, site-directed mutagenesis studies of the cpSRP43 SBD identified 
two classes of mutant cpSRP43s: Class I, which disrupts cpSRP43’s ability to protect LHCP from aggregation 
without affecting high-affinity recognition of L18; and Class II, which allosterically disrupts binding of the L18 
motif.  Together, these results provide evidence for much more extensive cpSRP43-client interactions, and 
suggest potential sites of cpSRP43 that interact with the TMDs of LHCP. 
When mapped onto the crystal structure of the cpSRP43 SBD, the two classes of mutants are enriched in different 
regions of the cpSRP43 SBD, suggesting that different surfaces in the SBD mediate distinct functions. The 
residues that give rise to Class II mutants are primarily located on the helixes in the ARM (Figure 4B, purple). As 
the sites of Class II mutations are away from the previously identified L18 binding site (Tyr204; highlighted in 
blue in Figure 4), we attribute their defects to disruption of the active conformation of the cpSRP43 SBD. In 
contrast, residues that give rise to Class I mutants are enriched in the bridging helix, the β-hairpins in the ARM, 
and a hydrophobic surface in CD1 (Figure 4A, orange), suggesting that these regions may either form or are in 
close vicinity to the TMD binding sites in cpSRP43. In support of this notion, Class I mutations cluster on or near 
major hydrophobic surfaces on the cpSRP43 SBD (Figure 4C). This model is also consistent with the general 
structural and functional features of ankyrin repeat proteins, which are formed by individual repeats of helix-
loop-helix folds connected by β-hairpins.  Structural, computational, and protein engineering studies showed that 
intra- and inter-repeat interactions between the helices allow ankyrin repeat proteins to cooperatively fold into 
concave L-shaped structures; in contrast, the loops and β-hairpins, which project outward from the helices, often 
form the recognition sites for interaction partners (31-32).  We therefore propose that client recognition by 
cpSRP43 may occur analogously, with the L18 sequence specifically recognized by the loop in Ank3, while the 
TMDs in LHCP are bound to and protected by the β-hairpins and the hydrophobic surface on Ank4 and BH.  
The large number of residues in the cpSRP43 SBD,  
at which a single conservative mutation away from the direct interaction site severely disrupts substrate binding 
and chaperone activity, is extraordinary. This behavior is characteristic of molecular systems that do not robustly 
attain the active conformation, such that small perturbations of any interaction are sufficient to drive the molecule 
or complex into the inactive state (33-34).  Likewise, the sensitivity of cpSRP43 to point mutations strongly 
suggests that its SBD is at the tipping point of a cooperative conformational change required to attain a 
chaperone-active conformation. This model is consistent with recent NMR data that detected distinct 
conformational states in the cpSRP43 SBD and showed a conformational equilibrium close to unity between the 
active and inactive states (25). As observed previously, this property of cpSRP43 may be particularly useful in 
enabling regulation, allowing cpSRP43 to be readily switched ‘on’ and ‘off’ by its regulators in the stroma and at 
the target membrane, respectively (25). The precise nature of the conformational changes in cpSRP43 remains an 












Protein Expression and Purification. Single cysteine mutants of Lhcb5 and cpSRP43 were constructed using the 
QuikChange Mutagenesis procedure (Stratagene) according to manufacturer’s instructions. WT and mutant 
cpSRP43, LHCP, and Lhcb5 were overexpressed and purified as previously described (35). 
 
Alkylation. Purified cpSRP43 and single-cysteine mutants of Lhcb5 were incubated in Buffer D (200 mM NaCl, 
50 mM KHEPES, pH 7.5) and treated with 4 mM TCEP overnight. Four µM Lhcb5 and cpSRP43 were incubated 
for 10 minutes to allow complex formation. Alkylation reactions were performed and analyzed as described 
previously (30). Briefly, the pre-formed Lhcb5-cpSRP43 complex was treated with 100 µM N-ethylmaleimide 
(NEM) for 2 or 10 minutes and quenched with 50 mM DTT. Quenched samples were treated with 0.2% formic 
acid and analyzed on an LC-MSD SL 1100 series (Agilent) using  a 2.1 x 150 mm Zorbax 300SB-C3 column 
(Agilent) and a gradient consisting of 0.2% formic acid as solvent A and 0.2% formic acid in acetonitrile (89.8%) 
and methanol (10%) as solvent B.  Intact masses were determined in the single quadrupole. Chemstation software 
(Agilent) was used to deconvolute the masses and quantify the proteins. The reported accessibilities were 
calculated as a ratio of the alkylation efficiency of each cysteine mutant observed in the cpSRP43-Lhcb5 complex 
relative to that of the same mutant denatured in 6M GdmCl. As a control, chaperone activity of cpSRP43 with 
each Lhcb5 mutant was monitored (Table 1) to ensure efficient complex formation for all Lhcb5 mutants with 
chaperone. 
 
Chaperone Activity of cpSRP43. The ability of cpSRP43 to prevent LHCP aggregation was measured as 
described (17, 28). Aggregates were removed via ultracentrifugation in a TLA-100 rotor (Beckman Coulter) at 
100,000 rpm for 30 min at 4°C prior to the experiment. Light scattering experiments were performed by addition 
of 3 µL of 50 µM LHCP denatured in 8M urea to 150 µL buffer D (50 mM KHEPES, pH 7.5, 200 mM NaCl) or 
2.5 µM cpSRP43 in buffer D. Light scattering was monitored at 360 nm on a UV-Vis spectrometer (Beckman 
Coulter) over time until equilibrium was reached. The percentage of soluble LHCP (% soluble) at equilibrium 
was plotted for each single-cysteine cpSRP43 mutant. 
 
Sedimentation. Aggregates of purified LHCP and cpSRP43 WT and mutants were removed via 
ultracentrifugation in a TLA-100 rotor (Beckman Coulter) at 100,000 rpm for 30 min at 4°C prior to the 
experiment. Sedimentation was performed by adding LHCP to either buffer D (50 mM KHEPES, pH 7.5, 200 
mM NaCl) alone or buffer D pre-incubated with cpSRP43 to a final concentration of 2.5 µM LHCP and 9.375 
µM cpSRP43. Chaperone was left to prevent LHCP aggregation for 10 minutes at room temperature, and then 
samples were spun down at 18,000 g for 30 minutes at 4°C in an Eppendorf microcentrifuge. The soluble 
fractions were removed from each tube after sedimentation and pellet fractions were resuspended in an equal 
volume of 8M urea. Equal volumes of pellet and soluble were run on gels that were Coomassie-stained and 
quantified using ImageJ. 
 
Translocation. Translocation was performed by incubating in vitro translated 35S-labeled LHCP that had been 
alone in aqueous buffer or prevented from aggregation or disaggregated with WT cpSRP43 with purified 
thylakoid membranes, 300 µM cpFtsY, 300 µM cpSRP54, 75 mM ATP, and 75 mM GTP at room temperature 
for 30 minutes with light. Gels were visualized via autoradiography and quantified via ImageJ. 
 
Measurement of L18 binding. The L18 binding affinity of cpSRP43 was measured using L11 
(GSFDPLGLADD), the minimal binding motif in L18, conjugated to HiLyte-Fluor488. Anisotropy 
measurements were conducted in buffer D (50 mM KHEPES, pH 7.5, 200 mM NaCl) on a Fluorolog 3-22 
spectrofluorometer (Jobin Yvon), using 100 nM HiLyte-Fluor488-labeled L11 and varying concentrations of 
cpSRP43. Samples were excited at 500 nm and fluorescence anisotropy was recorded at 527 nm, as previously 
described (25). The data were fit to Eq 1, 
𝐴!"# = 𝐴! + ∆𝐴
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in which [pro] is cpSRP43 concentration, Aobsd is the observed anisotropy value, A0 is the anisotropy value 
without cpSRP43, ∆A is the change in anisotropy at saturating cpSRP43 concentrations, and Kd is the equilibrium 
dissociation constant for the interaction of cpSRP43 with L11-HiLyte-Fluor488. 
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Table 1. Chaperone activity of cpSRP43 towards individual Lhcb5 single-cysteine mutants (columns 2 and 3), 
and NEM alkylation efficiency at each cysteine in the presence of WT cpSRP43 (columns 4 and 5).  acpSRP43 
chaperone activity was measured using 1 µM Lhcb5 in the light scattering assay. % soluble Lhcb5 at indicated 
cpSRP43 concentrations are reported. bFraction of NEM modified Lhcb5 in the cpSRP43•Lhcb5 complex after 
indicated times of the alkylation reaction. All values represent mean ±S.D., with n = 2. N.D., not done. 
 
Lhcb5 Construct 1 µM cpSRP43 
Activitya 
5 µM cpSRP43 
Activitya 
Alkylationb at 2’ Alkylationb at 10’ 
I40 ND ND 1.0 1.0 
G50 ND ND 1.0 1.0 
Q70 ND ND 0.55 ± 0.02 0.67 ± 0.10 
I75 84.48 ND 0.53 ± 0.05 0.66 ± 0.10 
A85 102.15 ± 0.66 ND 0.33 ± 0.00 0.39 ± 0.02 
P90 57.06 ± 31.69 ND 0.19 0.37 ± 0.14 
C100 (WT) 95.59 ND 0.62 ± 0.16 0.66 ± 0.17 
G110 ND ND 0.29 ± 0.05 0.35 ± 0.03 
N120 ND ND 0.47 ± 0.04 0.52 ± 0.09 
N125 74.62 ND 0.47 ± 0.00 0.56 ± 0.11 
L130 68.18 ± 0.24 ND 0.28 ± 0.00 0.32 ± 0.01 
V135 89.89 ± 14.78 ND 0.13 0.18 ± 0.01 
G143 89.20 ND 0.34 0.45 ± 0.01 
T150 95.84 ND 0.80 0.88 ± 0.03 
E156 80.74 ND 1.0 1.0 
D157 86.34 ND 1.0 1.0 
G162 95.39 ND 1.0 1.0 
A171 86.33 ND 1.0 1.0 
L180 89.85 ND 0.91 ± 0.12 0.91 ± 0.13 
I185 82.86 ± 5.02 ND 0.91 ± 0.12 0.86 ± 0.02 
L190 59.79 95.04 0.44 ± 0.10 0.48 ± 0.11 
M195 74.87 ± 23.58 95.50 0.17 ± 0.02 0.24 ± 0.05 
I200 77.24 ND ND 0.25 ± 0.10 
V210 92.27 ND 0.81 0.91 ± 0.13 
P220 88.82 ND 0.44 0.50 ± 0.17 







Table 2. Kd values for binding of HiLyte-conjugated L11 to individual cpSRP43 mutants. All cpSRP43 mutants 
shown in this table are derived from cysteine-less cpSRP43 (denoted as WT). Green highlights mutants that 
exhibit Kd values within 3-fold of WT cpSRP43; yellow highlights mutants exhibiting 3-5 fold defects in L11 
binding; and red highlights mutants that are severely defective in L11 binding. * indicates that saturation could 
not be reached with the mutant during equilibrium titrations, and their Kd values for L11 were estimated assuming 
the same end point in the titration curve as cysteine-less cpSRP43. 
 
 
Construct Average Kd (µM) 
WT 0.12 ± 0.029 
L103C 0.14 ± 0.052 
W106C 0.19 ± 0.027 
W114C 3.03  ± 0.61 
V124C 0.18 ± 0.058 
V125C 0.78 ± 0.058 
W133C 17.5* ± 3.65 
V156C 0.55 ± 0.17 
T162C 12.2* ± 0.44 
F166C 3.53 ± 0.44 
G193C 0.53 ± 0.16 
G194C 2.38 ± 0.61 
L195C 14.8* ± 5.26 
T196C 0.87 ± 0.14 
V222C 0.83 ± 0.22 
L228C 0.083 ± 0.066 
L231C 0.41 ± 0.029 
I237C 0.17 ± 0.078 
L238C 2.05 ± 0.19 
R252C 0.42 ± 0.18 
E256C 0.64 ± 0.017 
I259C 0.94 ± 0.26 
N260C 0.062 ± 0.0035 








Figure 1. Alkylation pattern of Lhcb5 in the cpSRP43•Lhcb5 complex suggests potential sites of chaperone interaction on the substrate 
protein. (A, B) Mass spectrum (upper left), deconvolution (lower left), and component analysis (upper right) for a completely alkylated Lhcb5 
residue, E156C (part A) and a partially alkylated Lhcb5 residue, V135C (part B). (C) Summary of the NEM alkylation efficiencies at 
individual sites in Lhcb5. Alkylation reactions were carried out for 10 minutes.  For each engineered cysteine, ‘Fraction Accessible’ was 
calculated from the ratio of the fraction of alkylation in the cpSRP43•Lhcb5 complex relative to that of Lhcb5 dissolved in 6M GdmHCl. 
Error bars indicate S.E.M., with n = 2. (D) The alkylation pattern of Lhcb5 in complex with cpSRP43 is mapped onto the sequence of Lhcb5. 
Red, green, and blue triangles denote extensive protection (<45% alkylation), intermediate levels of protection (45-75% alkylation), and least 









Figure 2. Single-cysteine mutants across the cpSRP43 SBD exhibit defects in chaperone activity. (A) Structure of cpSRP43 indicating all sites 
where cysteine mutations were made (blue). (B, C) Representative data showing the chaperone activity of neutral (part B) and defective (part 
C) cpSRP43 mutants. Light scattering traces are shown for LHCP diluted into aqueous buffer (green), into a solution containing cysteine-less 
WT (black), and into solutions containing the indicated cpSRP43 mutants. (D) Summary of the chaperone activity for all the single-cysteine 
mutants in the cpSRP43 SBD. Mutants exhibiting chaperone activity within three-fold that of cysteine-less cpSRP43 are considered neutral 
(above dashed line), whereas mutants with lower activity are considered defective (below dashed line).  Error bars indicate S.E.M, with n = 3-
13. (E) Sedimentation experimental results mirror trends observed through light scattering, supporting the classification of defective 
cpSRP43 single-cysteine mutants. Error bars indicate S.D., with n = 2. (F) Representative example of translocation with LHCP that has been 
prevented from aggregation or disaggregated by WT cpSRP43. (G) Correlation of % soluble LHCP with % translocation into thylakoid 







Figure 3. Characterization of the interaction of mutant cpSRP43s with the L18 motif. (A, B) Representative equilibrium titrations for the 
binding of WT and mutant cpSRP43s to Hylite-Fluor488 labeled L11.  Representative data for cpSRP43 mutants that can bind L11 with 
high affinity are shown in part A, and those for mutants exhibiting weakened L11 binding are shown in part B. (C) Summary of the 
cpSRP43-induced changes in the fluorescence anisotropy of L11 at 0.19 µM, which is subsaturating for the binding of cysteine-less cpSRP43 








Figure 4. (A) Residues whose mutations led to defective chaperone activity for LHCP (measured in Figure 2D) but did not disrupt L18 
binding (measured in Figure 3) are mapped onto the crystal structure of the cpSRP43’s SBD (PDB ID 3DEP).  These mutants are categorized 
as Class I and colored in orange. (B) Residues whose mutations disrupted both cpSRP43’s chaperone activity and its interaction with the L18 
motif are mapped onto the crystal structure of the cpSRP43 SBD. These mutants are categorized as Class II and colored in purple. (C) A 
putative model for the interaction surfaces of cpSRP43 with LHCP, with Tyr204 (blue) interacting with the L18 sequence, and the 

















Supplemental Table 1. Summary of L18 truncation experiments that identified L11 as the minimal motif of L18 
necessary and sufficient for binding to cpSRP43. 
 
LHCP Construct L18 Motif Prevention Disaggregation 
Wild type VDPLYPGGSFDPLGLADD Full Full 
Construct 1           YPGGSFDPLGLADD Full Full 
L11                   GSFDPLGLADD Full Full 
Construct 3                GGSFDPLGL None None 
Construct 4                          DPLGLADD None None 
Construct 5                        FDPLGL None None 
Construct 6                          DPLG None None 
Construct 7                   GSFDPLGLAD Partial Partial 
Construct 8                   GSFDPLGLA Partial Partial 
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Membrane protein biogenesis poses enormous challenges to cellular protein homeostasis and 
requires effective molecular chaperones. Compared with chaperones that promote soluble protein 
folding, membrane protein chaperones require tight spatiotemporal coordination of their substrate 
binding and release cycles. Here we define the chaperone cycle for cpSRP43, which protects the 
largest family of membrane proteins, the light harvesting chlorophyll a/b-binding proteins 
(LHCPs), during their delivery. Biochemical and NMR analyses demonstrate that cpSRP43 
samples three distinct conformations. The stromal factor cpSRP54 drives cpSRP43 to the active 
state, allowing it to tightly bind substrate in the aqueous compartment. Bidentate interactions with 
the Alb3 translocase drive cpSRP43 to a partially inactive state, triggering selective release of 
LHCP’s transmembrane domains in a productive unloading complex at the membrane. Our work 
demonstrates how the intrinsic conformational dynamics of a chaperone enables spatially 
coordinated substrate capture and release, which may be general to other ATP-independent 







Protein homeostasis is essential for all cells and requires proper control of the folding, localization, 
and interactions of proteins. The biogenesis of membrane proteins poses a particular challenge to 
protein homeostasis. Before arrival at the membrane, newly synthesized membrane proteins need 
to traverse aqueous cellular compartments where they are highly prone to aggregation. Thus, the 
posttranslational targeting of membrane proteins relies critically on effective molecular chaperones 
that maintain nascent membrane proteins in translocation competent states. Many examples 
illustrate the intimate link between chaperone function and membrane protein biogenesis: SecB, 
Skp, and SurA protect bacterial outer membrane proteins (1–5), and Hsp70 homologs assist the 
import of mitochondrial or chloroplast proteins (6). Our understanding of membrane protein 
chaperones lags far behind that for soluble proteins, such as DnaK and GroEL. All chaperones 
need to switch between “open” and “closed” conformations to allow substrate release and binding, 
respectively. For many chaperones that promote the folding of soluble proteins, these switches can 
be driven either by ATPase cycles, such as Hsp70 (7) and GroEL (8), or by changes in 
environmental conditions, such as the acid-induced HdeA (9, 10) and oxidation-induced Hsp33 
(11). In contrast, membrane protein chaperones must regulate their action spatially: they must 
effectively capture substrate proteins in the aqueous phase, and then facilely and productively 
release them at the target membrane. With few exceptions (1, 2), how membrane protein 
chaperones achieve spatiotemporal coordination of their chaperone cycle is not well understood.  
The light harvesting chlorophyll a/b-binding proteins (LHCPs) provide an excellent model system 
to address these questions. Like >95% of organellar proteins, LHCPs are initially synthesized in 
the cytosol and imported across the chloroplast envelope in a largely unfolded state with the 
assistance of the LHCP translocation defect protein (12). In the stroma, LHCPs are protected in a 
soluble “transit complex” by the chloroplast signal recognition particle (cpSRP), comprised of 
cpSRP43 and cpSRP54 (13). Via interactions between the GTPase domains of cpSRP54 and its 
receptor cpFtsY, LHCPs are delivered to the Alb3 translocase and inserted into the thylakoid 
membrane (13–17). LHCPs comprise more than 50% of the proteins in the thylakoid membrane 
and are the most abundant membrane protein family on earth. Their sheer abundance, high 
aggregation propensity, and crucial roles in energy generation of green plants demand highly 
effective chaperone(s) during their biogenesis, making this a robust system to understand the 
function and mechanism of membrane protein chaperones.  
Previous work showed that the cpSRP43 subunit in cpSRP binds tightly to and quantitatively 
prevents the aggregation of multiple members of the LHCP family, demonstrating that cpSRP43 is 
responsible for chaperone function (18, 19). cpSRP43 is comprised of multiple protein-interaction 
domains: three chromodomains (CDs) and an ankyrin repeat domain (A1–A4) between CD1 and 
CD2 (Fig. 1A) (14). Biochemical and crystallographic analyses showed that a conserved Tyr204 in 
the third ankyrin repeat recognizes a FDPLGL motif in L18, a conserved 18-amino acid sequence 
between TM2 and TM3 of LHCP (20– 22). In addition, aromatic cages in CD2 provide binding 





cpSRP54 can induce compaction of cpSRP43 and enhance L18 peptide binding threefold, 
suggesting that cpSRP54 could positively regulate cpSRP43 (24). Finally, cpSRP43 also interacts 
directly with the C-terminal stromal domain of the Alb3 translocase (termed Alb3CT) that 
mediates the membrane insertion of LHCP (25–29), suggesting a potential mechanism to couple 
substrate release to the correct localization of LHCP and its imminent membrane insertion (30). 
The ability of cpSRP43 to directly bind Alb3 may also explain findings in earlier genetic studies 
that, when both cpSRP54 and cpFtsY are deleted, cpSRP43 by itself can mediate the targeting and 
insertion of some LHCP family members, albeit less efficiently (30).  
Nevertheless, the molecular mechanism of cpSRP43’s chaperone function remains elusive. Where 
is the substrate binding domain of this chaperone located? How does it interact with the targeting 
(cpSRP54) and translocation (Alb3) machineries to achieve accurate spatiotemporal regulation of 
its activity? More fundamentally, in the absence of an ATPase module, what propels the substrate 
binding and release cycle for this chaperone? In this work, a combination of biochemical and 
solution NMR studies addresses these questions and for the first time, to our knowledge, defines 
the complete chaperone cycle for a chaperone dedicated to integral membrane proteins. Our results 
show that cpSRP43 inherently exchanges between three distinct conformations; this allows it to be 
readily turned “on” by cpSRP54 in the aqueous stroma to enable tight substrate binding and to be 
readily switched to less active conformations by Alb3 at the membrane to enable facile substrate 
unloading. Furthermore, we show that Alb3 specifically induces the release of substrate TMDs, but 
not the L18 motif, from cpSRP43, suggesting a highly productive, stepwise mechanism for 







Defining the Substrate-Binding Domain for 
cpSRP43  
In previous work, a fragment comprising CD1 
and the ankyrin repeat domain of cpSRP43 
(CD1Ank) could not chaperone LHCP (19). 
Nevertheless, crystallographic analysis (20) 
revealed an additional 20-amino acid-long helix, 
not present in other ankyrin repeat proteins, that 
bridges the ankyrin repeat domain and CD2 (here 
termed the bridging helix or BH; Fig. 1A). 
Intriguingly, addition of this BH to CD1Ank was 
necessary and sufficient to restore chaperone 
activity. Using a light scattering assay (19), 
which directly monitors the formation of large 
protein aggregates, we found that a protein 
fragment containing CD1, the ankyrin repeat 
domain, and BH (CD1Ank-BH) prevented the 
aggregation of LHCP fivefold more efficiently 
than full-length cpSRP43 (Fig. 1B). In a more 
stringent disaggregation assay (19), which 
monitors the ability of cpSRP43 to reverse 
preformed large LHCP aggregates, CD1Ank-BH 
was also more efficient than full-length cpSRP43 
(Fig. 1C). Consistent with previous results (19), 
removal of BH (i.e., CD1Ank) abolished 
chaperone activity in both assays (Fig. 1 B and 
C). A key substrate recognition motif of 
cpSRP43 is the L18 sequence between TM2 and 
TM3 of LHCP (21, 31). To test whether the BH 
is important for this recognition, we measured 
cpSRP43 binding with L18 based on the increase 
in fluorescence anisotropy of a HiLyte-
Fluor488–labeled L11 peptide, which comprises 
the minimal binding motif in L18 (20, 22). The 
CD1Ank-BH fragment binds tightly to the dye-
labeled L11 peptide, with a Kd value (15 nM) twofold lower than that of WT cpSRP43 (25 nM) 
(Fig. 1D). Consistent with the results of the light scattering assay, removal of the BH abolished this 
binding (Fig. 1D). To rule out potential artifacts introduced by dye labeling, we also measured the 
binding of the WT L18 sequence to cpSRP43 by using it as a competitor of dye-labeled L11 in the 
Figure 9. The CD1Ank-BH fragment is necessary and sufficient for 
the chaperone activity of cpSRP43. (A) Schematic of cpSRP43. CD, 
chromodomain; A1–A4, ankyrin repeats 1–4; BH, bridging helix; 
SBD, substrate binding domain. (B) Binding of LHCP to wildtype 
cpSRP43 (black) and to the CD1Ank (green) and CD1Ank-BH 
(red) fragments of cpSRP43 were measured by the ability of 
cpSRP43 to prevent LHCP aggregation (Materials and Methods). 
The data were fit to Eq. 1 and gave apparent Kd values of 170 and 
32 nM for LHCP binding to cpSRP43 and to the CD1Ank-BH 
fragment, respectively. (C) CD1Ank-BH (red) can reverse LHCP 
aggregation more efficiently than WT cpSRP43 (black), but the 
CD1Ank (green) fragment cannot. (D) Binding of HiLyte-Fluor 
488–labeled L11 peptide to WT and mutant cpSRP43, detected by 
fluorescence anisotropy. The data were fit to Eq. 2 and gave Kd 
values of 25 and 15 nM for the binding of dye-labeled L11 peptide 
to cpSRP43 (black) and to the CD1Ank-BH (red) fragment, 
respectively. (E) Binding of the L18 peptide to WT and mutant 
cpSRP43 was measured using L18 as a competitor of dye-labeled 
L11. The data were fit to Eq. 3 and gave Kiapp values of 1.1 and 0.5 
µM for cpSRP43 (black) and the CD1Ank-BH (red) fragment, 
respectively. Errors of Kd and Kiapp values were estimated to be 






anisotropy assay. These experiments showed that L18 effectively bound to both WT cpSRP43 and 
CD1Ank-BH and competed with dye-labeled L11 (Fig. 1E). Together with previous mutational 
analyses (19), these results establish that the CD1Ank-BH fragment comprises the minimal 
substrate binding domain (SBD) of cpSRP43 and that the bridging helix connecting the ankyrin 
repeat domain to CD2 is crucial for substrate binding.  
Chromodomain 2 Regulates Chaperone Activity 
Intriguingly, we isolated many mutations in the neighboring 
CD2 that affect chaperone activity of the SBD. One class of 
these mutants resides in the linker connecting BH to CD2 
(Fig. 2A, cyan). The chaperone activity of cpSRP43 is 
strongly correlated with the flexibility of the linker 
sequence, with longer and more flexible linkers [GSCFNGT 
(the Intein construct) or GSGSG insertion], leading to 
higher activities of cpSRP43 in preventing (Fig. 2B) and 
reversing (Fig. 2C) LHCP aggregation, whereas a 
conformationally more restricted linker 2P (two Pro 
replacing the natural QV) leads to lower activity (Fig. 2 B 
and C). A second class of mutants resides in the conserved 
hydrophobic core of CD2 (Fig. 2A, yellow). Virtually every 
single mutation introduced into this core hyperactivates the 
chaperone (Fig. 2D). Quantitative analysis of some of the 
chaperone (Fig. 2D). Quantitative analysis of some of the 
mutants further showed that cpSRP43’s substrate binding 
is enhanced 10- to 20-fold in each mutant (Fig. 2 E and F). 
Thus, although CD2 does not directly bind the substrate 






Figure 10. Mutations in CD2 hyperactivate the chaperone. (A) Crystal structure of cpSRP43 CD1Ank-BH-CD2 fragment bound to 54M 
peptide [Protein Data Bank (PDB) ID code 3UI2]. Cyan shows the linker (V266, F267) between BH and CD2, yellow shows residues 
mutated in the hydrophobic core of CD2, magenta highlights the BH, and red shows the 54M peptide. (B and C) Chaperone activity of 
cpSRP43 linker mutants, measured by prevention (B) and reversal (C) of LHCP aggregation. The data in B were fitted to Eq. 1 and gave 
apparent Kd values of 33, 100, 177, and 256 nM for LHCP binding to intein-cpSRP43 (red), GSGSG-cpSRP43 (orange), WT cpSRP43 
(black), and 2P-cpSRP43 (cyan), respectively. (D) Many point mutations in the conserved hydrophobic core of CD2 activate chaperone 
activity. Chaperone activities were measured by prevention of LHCP aggregation using 1 µM LHCP and 4 µM WT or mutant cpSRP43. 
Error bars represent SD, with n = 2. To rule out potential involvements of CD3, all measurements were made with the ΔCD3 construct. 
A soft mutation, C175A, was present in all constructs to increase the sensitivity of the mutational screen under these conditions. (E and 
F) Mutants Y287R (E) and W299R (F) enhance LHCP binding to cpSRP43 >10-fold. Chaperone activities were measured and analyzed 
as in B and gave apparent Kd values of 1.9 µM, 168 nM, and 141 nM for cpSRP43(C175A), cpSRP43(Y287R_C175A), and 










The cpSRP54 M Domain Drives cpSRP43 to the Active Conformation 
 
In the stroma, cpSRP43 is bound to cpSRP54, the other subunit of cpSRP. The C terminus of the 
cpSRP54 M-domain (termed 54M) binds at CD2 in the vicinity of the BH (Fig. 2A) (23, 32), 
placing it in an optimal position for regulating interdomain interactions of cpSRP43. In support 
of this notion, 54M enhances the binding affinity of LHCP to WT cpSRP43 sixfold under 
stringent low salt conditions (100 mM NaCl; Fig. 3A). This result is consistent with a recent 
study, which also reported that cpSRP43 
becomes more compact and binds the L18 
peptide threefold more strongly in the 
presence of cpSRP54 (24). Importantly, the 
superactive mutant, intein-cpSRP43, is not 
further stimulated by 54M (Fig. 3B). In 
contrast, a soft mutation C175A reduced 
cpSRP43’s chaperone activity ∼18-fold; this 
partially crippled mutant is much more 
strongly activated by 54M (Fig. 3C). 
Together, these results strongly suggest that 
54M and superactive mutations in CD2 drive 
the same activating conformational change in 
cpSRP43 and that interdomain dynamics 
control cpSRP43’s chaperone activity (Fig. 
3D). CpSRP43 has been bound to shift 
between monomer and higher oligomeric 
forms depending on solution ionic strength 
(19). To test whether the activating 
conformational change of cpSRP43 is related 
to changes in its oligmeric state, we carried 
out gel filtration chromatography and 
analytical ultracentrifugation analyses.  
The results showed that, under high salt 
conditions (≥200 mM NaCl), WT or 
superactive intein-cpSRP43 is predominantly 
a monomer. cpSRP43 also binds the L11 peptide and 54M in monomeric form. Under low salt 
conditions (50 mM NaCl), cpSRP43 predominantly runs on Superdex 200 as a dimer as 
previously observed (19). Importantly, binding of L11 shifts dimeric cpSRP43 toward the 
monomeric form. These results, together with the previous observation that the shift of cpSRP43 
to dimeric complexes at lower ion strength is correlated with loss of chaperone activity (19), 
strongly suggest that monomeric cpSRP43 is chaperone active. Thus, the substrate- and 54M 
induced rearrangement of cpSRP43 reflects an intramolecular conformational change, rather than 
changes in its oligomeric state. 
 
Figure 11. The cpSPR54 M-domain activates cpSRP43 for 
substrate binding. The abilities of chaperone to prevent LHCP 
aggregation were measured for WT cpSRP43 (A), superactive 
intein-cpSRP43 (B), and partially defective mutant 
cpSRP43(C175A) (C) in the absence (●) and presence (○) of 54M. 
The data were fit to a Michaelis–Menton equation and gave 
apparent Kd values of 0.26 and 1.5 µMfor WT cpSRP43 with and 
without 54M (A), 0.20 and 0.41 µMfor intein-cpSRP43 with and 
without 54M (B), and 0.08 and 3.0 µM for cpSRP43(C175A) with 
and without 54M (C). In A and B, activities were measured under 
100 mM NaCl, a stringent condition under which cpSRP43 
exhibits slightly reduced activity, to overcome the saturation 
effects with highly active chaperone constructs and better reveal 
the stimulatory effects of 54M. (D) Scheme depicting the 







NMR Spectroscopy Directly Reveals Chaperone Conformational Dynamics 
 
To directly probe for conformational dynamics in cpSRP43, we used transverse relaxation 
optimized (TROSY) NMR spectroscopy. We assigned the cpSRP43 backbone resonances using 
3D triple resonance TROSY spectra of 2H,13C,15N-labeled cpSRP43 and the CD1Ank-BH 
fragment; assignments for several CD2 cross-peaks in full-length cpSRP43 were obtained by 
transferring published assignments of the isolated CD2CD3 fragment (33). We were able to 
assign the amide 15N, 1HN, 13Cα, and 13Cβ resonances for 80% of residues. Intriguingly, the 
number of NMR cross-peaks in the 1H-15N TROSY spectrum of cpSRP43 far exceeded the 
number of residues in the protein. This puzzle was resolved during NMR assignments: we found 
that at least 12 residues in CD1 (highlighted in Fig. 4G in blue) give rise to two 1H-15N cross-
peaks in the TROSY spectrum that have identical 13Cα and 13Cβ chemical shifts (examples for 
S92 and A95). This observation indicates that the component cross-peaks in the TROSY spectra 
arise from the same amino acids and represent two distinct conformations of cpSRP43 in slow 
exchange on the chemical shift timescale. Importantly, the relative intensities of the component 
crosspeaks change in different constructs and in response to different ligands. An example for 
S92 is shown in Fig. 4. In full-length cpSRP43, the intensities of the twocomponent cross-peaks 
are comparable (Fig. 4B). In the inactive CD1Ank construct, the upfield peak is dominant (Fig. 
4A). In contrast, in the CD1Ank-BH construct or the superactive mutant intein-cpSRP43, which 
binds LHCP two- to fivefold more tightly than full-length cpSRP43 (Figs. 1B and 2B), the 
downfield peak becomes more intense (Fig. 4 C and D). When cpSRP43 is bound to the L18 
peptide or to the activator, 54M, or the C-terminal peptide of 54M that binds cpSRP43 (54M 
peptide), the downfield peak is dominant (Fig. 4 E and F). Additional titration experiments with 
L18 and 54M peptide corroborated that the downfield peak can be assigned to the active 
conformation of cpSRP43 conducive to substrate binding. Further, the relative intensity of this 
peak is strongly correlated with chaperone activity (Fig. 4H). Collectively, the biochemical and 
NMR data demonstrate that the SBD of cpSRP43 exchanges between active and inactive 
conformations that are regulated by CD2, by the substrate, and by interaction with the cpSRP54 
M-domain. 
 
Figure 12. Conformational dynamics 
of cpSRP43 correlates with its 
chaperone activity. (A–F) 
Component cross-peaks for Ser92 in 
the TROSY spectrum of 
2H,15Nlabeled CD1Ank fragment 
(A), full-length cpSRP43 (B), 
CD1Ank-BH fragment (C), intein-
cpSRP43 (D), cpSRP43 bound to 
54M peptide (E), and cpSRP43 
bound to the L18 peptide (F). (G) 
Crystal structure of CD1Ank-BH 
fragment (PDB ID code 3DEP) 
highlighting the residues in CD1 
(blue) for which component cross 
peaks reflecting the conformational dynamics of cpSRP43 have been unambiguously assigned. Green shows Tyr204 in Ank3, which binds 
L18 (cyan). Magenta highlights the bridging helix. (H) Correlation between the chaperone activity (% soluble LHCP observed with 0.625 







Bidentate Interactions of Alb3 with cpSRP43 Drive Substrate Release 
 
Recent data showed that cpSRP43 directly 
interacts with the C-terminal stromal domain of 
Alb3 (Alb3CT). However, which site(s) in 
cpSRP43 interact with Alb3CT is extensively 
debated (25–27, 29). To resolve this question, 
we titrated Alb3CT into cpSRP43 and 
monitored changes in the TROSY spectra. We 
found that Alb3CT substantially (>90%) 
broadened a specific set of cross-peaks in CD3, 
in contrast to the absence of any substrate- or 
54M-induced perturbations in this domain. 
Many perturbed cross-peaks map to an extensive 
surface displaying conserved acidic residues and 
two aromatic residues (Fig. 5A), suggesting this 
to be a binding site for Alb3CT. This 
observation is consistent with a recent study in 
which a peptide corresponding to motif IV in 
Alb3CT is found to bind at an acidic surface in 
CD3 (29). 
 
Figure 13. Chromodomain 3 of cpSRP43 binds motif IV of Alb3CT. (A) A 
structural model of CD3 (PDB ID code 1X32) highlighting the mutated 
residues. (B) Binding of fluorescein-labeled Alb3CT(S371C) to WT and mutant 
cpSRP43 were measured by changes in fluorescence anisotropy. The data were 
fit to Eq. 2 and gave Kd values of 18, >60, >63, and >160 µM for WT cpSRP43 
and mutants 2RA, 3R, and ΔCD3, respectively. The anisotropy value of 
mutants was normalized to the same end point as WT cpSRP43. (C) Schematics 
of WT and charge reversal mutants of Alb3CT. (D and E) Binding of mutant 
Alb3CT(M4_5E) (D) and Alb3CT(M2_3E) (E) to WT cpSRP43 and mutant 
cpSRP43(3R), measured and analyzed as in B. The dashed lines indicate 
binding between WT Alb3CT and cpSRP43 from B and are shown for 
comparison. (F) Scheme for the LHCP TMD release assay. M2 and M4 denote 
Alb3CT motifs II and IV, respectively. (G–J) Alb3CTinduced TMD release 
from cpSRP43 for the reaction of WT cpSRP43 with mutant Alb3CT(M2_3E) 
(G), WT cpSRP43 with Alb3CT(M4_5E) (H), mutant cpSRP43(3R) with 
mutant Alb3CT(M2_3E) (I), and mutant cpSRP43(3R) with mutant 
Alb3CT(M4_5E) (J). The arrows indicate time of Alb3CT addition. Red, blue, 
and green indicate addition of 5, 10, and 20 µM Alb3CT, respectively. The 






To biochemically test this model, we generated two charge reversal mutants in CD3, 
E352R/D355R/D358R (3R; Fig. 5A, green), and E338R/Y339A/D348R/W351A (2RA; Fig. 5A, 
cyan). We measured the binding of 
Alb3CT to WT and mutant cpSRP43 
based on the anisotropy change of 
fluorescein labeled at Alb3CT(S371C). 
Consistent with previous measurements 
(25, 26), WT cpSRP43 bound Alb3CT 
with an equilibrium dissociation constant 
(Kd) of 18 µM in this assay. Binding was 
weakened ninefold on deletion of CD3 
(Fig. 5B, red), consistent with an 
important role of CD3 in cpSRP43-Alb3 
binding (25). Both charge reversal 
mutants in CD3, cpSRP43(3R) and 
cpSRP43 (2RA), weakened the binding of 
Alb3CT fourfold (Fig. 5B).Alb3CT 
contains two conserved motifs, II and IV, 
that could interact with cpSRP43 (Fig. 5C) 
(25). Both motifs, especially motif IV, are 
enriched in basic residues, providing 
strong candidates for interacting with the 
acidic patch in CD3. We therefore 
introduced charge reversal mutations into 
motif II (M2_3E) or motif IV (M4_5E) of 
Alb3CT (Fig. 5C). Both mutations 
significantly weakened the binding of 
Alb3CT to cpSRP43 (Fig. 5 D and E, blue). 
Importantly, when the charge reversal 
mutants cpSRP43(3R) and Alb3CT(M4_5E) 
were combined to restore electrostatic 
complementarity, binding was partially 
rescued (Fig. 5D, green). In contrast, rescue 
was not observed when cpSRP43(3R) was 
combined with mutant Alb3CT(M2_3E) 
(Fig. 5E, green). These results suggest a 
specific electrostatic interaction between 
motif IV in Alb3CT and the acidic surface 
in CD3 of cpSRP43. To provide additional evidence for this model and to probe the function of 
Alb3CT, we developed an independent assay in which a preformed, soluble cpSRP43•LHCP 
complex is challenged with Alb3CT. If interaction with Alb3CT releases substrate from cpSRP43, 
this would lead to aggregation of LHCP that can be monitored in real time using light scattering 
(Fig. 5F). Indeed, addition of Alb3CT led to the reappearance of large LHCP aggregates in a dose-
Figure 14. Bidentate interaction of Alb3CT with cpSRP43. (A) Alb3CT-
induced perturbation of cross-peaks in the TROSY spectra of 2H,15N-
labeled CD1Ank-BH fragment. Spectra in the absence and presence of 
Alb3CT are shown in black and red, respectively. (B) Structure of 
CD1Ank-BH (PDB ID code 3DEO) highlighting residues for which 
NMR cross-peaks are perturbed by Alb3CT. Red denotes residues for 
which cross-peaks are broadened >70%; blue denotes residues whose 
cross-peaks are shifted by Alb3CT. Green shows Tyr204 in Ank3 where 
L18 binds. (C) Schematic of the mutant Alb3CT constructs used in this 
study. ΔM2 and ΔM4 denote deletion of motifs II and IV, respectively, 
ΔL denotes deletion of linker sequence. (D) Binding of WT Alb3CT 
(black) and mutant ΔM2 (red) and ΔM4 (blue) to cpSRP43, measured 
by their ability to compete with fluorescein-labeled Alb3CT(S371C) for 
binding to cpSRP43 and detected by fluorescence anisotropy. The data 
were fit to Eq. 3 and gave Kappi values of 41, 99, and 237 µM for WT 
Alb3CT and mutants ΔM2 and ΔM4, respectively. (E and F) LHCP 
release assays were carried out as outlined in Fig. 5F for WT Alb3CT 
(black), mutants ΔM2 (red) and ΔM4 (blue) (E), and mutants ΔL20 





dependent manner. This result indicates that the hydrophobic TMDs of LHCP are no longer 
protected by cpSRP43 on Alb3CT binding and provides a robust assay to analyze the interaction 
and activity of Alb3CT. Both charge reversal mutants of Alb3CT, M2_3E and M4_5E, display 
severely compromised activities in this release assay (Fig. 5 G and H), supporting the importance 
of both motifs in Alb3CT activity. Importantly, combining the charge reversal mutant 
cpSRP43(3R) with Alb3CT(M4_5E) restored release activity (Fig. 5J), whereas the combination 
with Alb3CT(M2_3E) did not (Fig. 5I). Thus, in agreement with the recent structural analysis (29), 
cpSRP43 CD3 provides a platform to specifically bind motif IV in Alb3CT. Our results further 
show that this interaction is electrostatic in nature and important for the ability of Alb3CT to 
induce substrate release from cpSRP43. In addition to CD3, Alb3CT also induced substantial 
broadening of 17 cross-peaks in the TROSY spectrum of cpSRP43 that map to the SBD. This 
observation was corroborated when the TROSY experiment was repeated with the CD1Ank- BH 
construct: even in the absence of CD2 and CD3, addition of Alb3CT-induced broadening or shifts 
of a specific set of cross-peaks in the TROSY spectrum of CD1Ank-BH (Fig. 6A). Seven of the 
Alb3CT-perturbed cross-peaks map to CD1; another three map to Ank3 (Fig. 6B). Thus, Alb3CT 
also contacts the SBD. The simplest model to explain these results is that Alb3CT makes bidentate 
interactions with cpSRP43 in both the SBD and CD3. To test this model, we deleted motif II or IV 
of Alb3CT (Fig. 6C, ΔM2 and ΔM4, respectively). We measured the binding of WT and mutant 
Alb3CT to cpSRP43 by using them as competitors of fluorescein-labeled Alb3CT in the anisotropy 
assay (Fig. 6D). ΔM2 and ΔM4 weakened the binding of Alb3CT to cpSRP43 two- and sixfold, 
respectively (Fig. 6D). Both mutations also abolished the ability of Alb3CT to trigger LHCP 
release from cpSRP43 (Fig. 6E). The same effects were observed with charge reversal mutations in 
Alb3CT motifs II and IV interaction between Alb3CT and cpSRP43 that are essential to release 
LHCP from cpSRP43 at the membrane translocase (Fig. 5 D, E, G, and H). Together, these data 
provide strong evidence that Alb3CT uses motifs II and IV to make bidentate interactions with 
cpSRP43. The much larger effects of each mutant in the LHCP release assay than on cpSRP43-
Alb3 binding (Fig. 6 D vs. E) further suggests that, although each motif could bind cpSRP43 at 
sufficiently high concentrations, the ability of Alb3CT to trigger substrate release requires the 
interactions mediated by both motifs. 
 
If a bidentate interaction with Alb3CT was required to release LHCP from cpSRP43, then the 
spacing between motifs II and IV would also be important for this activity. In WT Alb3, these two 
motifs are bridged by a ∼72-amino acid unstructured linker sequence, rendering it plausible that 
the two motifs can span the distance between the SBD and CD3 of cpSRP43. To test the 
importance of this spacing, we shortened the linker sequence (Fig. 6C, mutants ΔL20, ΔL40, and 
ΔL47). Although mutant ΔL20 did not exhibit a significant defect, further deletion of the linker 
sequence in mutants ΔL40 and ΔL47 compromised the ability of Alb3CT to induce LHCP release 
from cpSRP43 (Fig. 6F). Collectively, these data provide strong evidence for a bidentate 
interaction between Alb3CT and cpSRP43 that are essential to release LHCP from cpSRP43 at the 
membrane translocase. 
 






How does Alb3CT trigger substrate release from cpSRP43? Given that cpSRP43 samples between 
active and inactive conformations (Figs. 2–4), an attractive hypothesis is that Alb3CT drives 
cpSRP43 to a less active form. To test this model, we used two independent approaches. First, we 
took advantage of cpSRP43 variants, CD1Ank-BH and CD1Ank, which reside predominantly in 
the active and inactive conformations, respectively, and tested their binding with Alb3CT using the 
fluorescence anisotropy assay. We found that Alb3CT exhibits significant interactions with the 
CD1Ank fragment, although the 
interaction is 18-fold weaker than with 
full-length cpSRP43, consistent with 
the model that the SBD provides 
another binding site for Alb3CT (Fig. 
7A). Importantly, Alb3CT bound to the 
CD1Ank fragment two- to threefold 
more strongly than to the CD1Ank-BH 
fragment, suggesting that it 
preferentially interacts with a cpSRP43 
in a less active conformation. The 
stronger interaction of CD1Ank with 
Alb3CT than CD1Ank-BH also ruled 
out the possibility that irreversible 
misfolding of CD1Ank is responsible 
for its lack of chaperone activity. In the 
second approach, we took advantage of 
the TROSY spectra of cpSRP43, in 
which the relative intensity of 
component cross-peaks from individual 
amide groups directly detects cpSRP43 
subpopulations in active and inactive 
conformations. Of the 12 residues in 
cpSRP43 for which component cross-
peaks can be unambiguously assigned, 
residues S92, R93, Y102, L103 
exhibited an Alb3CT-induced increase 
in the relative intensity of the peak that 
arise from the inactive conformation 
(Fig. 7B). These results provide 
independent support for the model that Alb3CT biases cpSRP43 to a less active conformation. In 
the targeting pathway, Alb3CT must interact with and release substrates from the 
LHCP•cpSRP43•cpSRP54 complex. To test whether this is possible, we sequentially added the 
54M peptide, followed by Alb3CT, during 2D-TROSY experiments with the superactive intein-
cpSRP43 (to mimic the conformation of substrate-bound cpSRP43). For five residues (S92, R93, 
T94, Y102, and L103), the intensity of the component cross-peaks representing the inactive 
conformation was significantly reduced on the addition of 54M, but these inactive peaks regained 
Figure 15. Alb3CT preferentially binds and induces a less active conformation 
of cpSRP43. (A) Binding of Alb3CT to full-length cpSRP43 (black) and to the 
CD1Ank (green) and CD1Ank-BH (red) fragments, measured as in Fig. 5B. 
The data were fit to Eq. 2 and gave Kd values of 12, 216, and >530 µM for WT 
cpSRP43, CD1Ank, and CD1ANk-BH, respectively. Errors for Kd were 
estimated to be ±10% (SD) based on at least two technical replicates. (B) 
Region of the TROSY spectrum showing the component cross-peaks for Ser92 
in 2H, 15N-labeled cpSRP43 in complex with Alb3CT. (C) The relative 
intensities of the cross-peaks corresponding to the inactive chaperone 
conformation are reduced by 54M (red bars) and enhanced by subsequent 
addition of Alb3CT (green bars). Data are shown for indicated residues in 2H, 
15N-labeled inteincpSRP43. Relative intensities were determined from cross-
peak heights. (D) 54M and Alb3CT bind to intein-cpSRP43 simultaneously. 
The cross-peaks for Tyr287 in the TROSY spectra of 2H, 15N-labeled intein-
cpSRP43 are shown. The peak was shifted on 54M binding (red), and this 
perturbation persists on subsequent addition of Alb3CT (green). (E) Scheme 
depicting the cobinding of 54M and Alb3CT to cpSRP43. M2, Alb3CT motif 





significant intensity on subsequent addition of Alb3CT (Fig. 7C). The effect of Alb3CT did not 
arise from dissociation of 54M from cpSRP43, as the binding of 54M to cpSRP43 could be 
detected by shifts of specific cross-peaks corresponding to residues in and near CD2 (Fig. 7D), and 
the 54M-induced perturbation of these cross-peaks remained even after the addition of Alb3CT 
(Fig. 7D). Collectively, the biochemical and NMR data strongly suggest that Alb3CT induces 
cpSRP43 to a less active conformation (Fig. 7E). The fact that this transition was observed with 
only a subset of residues further suggests that Alb3CT does not drive cpSRP43 into the completely 
inactive form but rather induces structural transitions in part of the cpSRP43 molecule. This notion 
is further supported by results in the following section. 
 
Alb3CT Specifically Releases Substrate TMDs from cpSRP43  
 
Our previous work showed that cpSRP43 binds LHCP via two sets of interactions: recognition of 
the L18 motif in loop 2 and promiscuous hydrophobic interactions with the TMDs in LHCP (22). 
When the cpSRP43•LHCP complex was challenged by Alb3CT in the release assay, the light 
scattering data indicated that Alb3CT antagonizes the interaction of substrate TMDs with 
cpSRP43 such that they are no longer protected from aggregation (Fig. 5F). To test whether 
Alb3CT also antagonizes the interaction of cpSRP43 with the L18 motif, we measured the 
binding of HiLyte-Fluor488–labeled L11 peptide to cpSRP43 based on fluorescence anisotropy 
(Fig. 8A). Intriguingly, the binding of L11 to cpSRP43 was unaffected, if not slightly stronger, in 
the presence of Alb3CT (Fig. 8A). To rule out artifacts from dye labeling, we also measured the 
binding of unlabeled L18 peptide to cpSRP43 by using it as a competitor of dye-labeled L11 
(Fig. 8B). This experiment yielded the same result: L18 binds to cpSRP43 with comparable 
affinity with or without Alb3CT present. These data indicate that Alb3CT specifically 
antagonizes the interaction of cpSRP43 with the substrate TMDs, but does not affect the 
interaction of this chaperone with the L18 motif. 
 
To test this model in the context of full-length LHCP, we reperformed the LHCP release assay 
except that, instead of monitoring the release reaction by light scattering, we monitored FRET 
between a donor dye (Atto488) labeled in the L18 motif of LHCP (G158C) and an acceptor dye 
[tetramethylrhodamine (TMR)] labeled at the native Cys297 of cpSRP43. In contrast to the 
release of TMDs detected by light scattering, the FRET assay showed no changes in, if not 
slightly higher, FRET efficiency between LHCP-L18 and cpSRP43-CD2 when the 
cpSRP43•LHCP complex was challenged with Alb3CT (Fig. 8C), suggesting that Alb3CT did 
not induce the release of L18 from cpSRP43. Together, these results support a model in which 
Alb3CT induces cpSRP43 into a distinct conformation in which the substrate TMDs are released, 







Figure 16. Alb3CT uncouples the interaction of cpSRP43 
with the L18 motif and TMD of LHCP. (A) Binding of 
HiLyte-Fluor488–labeled L11 peptide to cpSRP43 with 
(blue) and without (red) Alb3CT present, measured using 
fluorescence anisotropy. The data were fit to Eq. 2 and 
gave Kd values of 22 and 11 nM in the absence and 
presence of 20 µMAlb3CT, respectively. (B) Binding of the 
L18 peptide to cpSRP43 in the absence (red) and presence 
(blue) of Alb3CT, measured by using L18 as a competitor 
of HiLyte-Fluor488–labeled L11 peptide in binding 
cpSRP43. The data were fit to Eq. 3 and gave Kappi 
values of 1.1 and 0.68 µM in the presence and absence of 
Alb3CT, respectively. (C) (Left) Scheme of the FRET-
based LHCP release assay (Materials and Methods). 
(Right) FRET efficiency between Atto488-labeled LHCP 
(at L18) and TMR labeled cpSRP43 before and after 
challenge by Alb3CT. Values reported are mean ± SD, 
with n = 2. (D) Model for the chaperone cycle of cpSRP43 
during LHCP targeting and insertion, as described in the 
text. TMD, transmembrane domain; SBD, substrate 









Membrane proteins pose special challenges to protein homeostasis during their posttranslational 
targeting and require highly effective chaperones. Compared with chaperones that facilitate the 
folding of soluble proteins, membrane protein chaperones not only handle much more aggregation-
prone client proteins, but must also regulate their substrate binding and release in response to 
spatial cues. Here, we define the complete chaperone cycle for cpSRP43, an ATP-independent 
chaperone dedicated to integral membrane proteins. Our results reveal a remarkably modular 
nature of this chaperone, wherein substrate binding and spatial regulations are mediated by distinct 
domains. Most importantly, the SBD of cpSRP43 intrinsically samples at least three distinct 
conformations. This conformational sampling enables this chaperone to be readily switched on by 
activators in the stroma and switched off by a negative regulator at the target membrane, driving 
highly coordinated substrate capture and release despite the lack of ATPase cycles. 
 
Substrate Binding Domain Samples Multiple Conformations  
 
Remarkably, a 25-kDa fragment in cpSRP43 comprised of CD1, the ankyrin repeats, and the 
bridging helix was sufficient for stoichiometric binding and chaperoning of LHCP by cpSRP43. 
Combined with previous mutational work that tested the effects of deleting CD1 and individual 
ankyrin repeats (19), this defines the CD1Ank-BH fragment as the minimal substrate binding 
domain for cpSRP43. How this small chaperone domain protects client proteins, which match its 
own size and contain three TMDs, will be the next challenging question. conformations. This 
property is most directly visualized in the 1H-15N TROSY spectra of cpSRP43, in which at least 
two distinct conformations in slow exchange gave rise to pairs of component cross-peaks for the 
same backbone NH. Although component cross-peaks are unambiguously assigned for 12 residues 
reported here, the number of cross-peaks in the TROSY spectrum is ∼50% greater than the number 
of residues in cpSRP43, indicating that many more residues undergo analogous conformational 
sampling. A recent single molecule study also revealed a high degree of conformational fluctuation 
in cpSRP43 (24). Our ability to isolate a large set of superactive and defective mutations that lock 
this chaperone into distinct conformations provides further evidence for this model. Importantly, 
the relative intensity of the component cross-peaks in the TROSY spectra strongly correlate with 
chaperone activity in different cpSRP43 variants and in the presence of different regulators (more 
discussions below). Based on these observations, we propose that the SBD samples between an 
open conformation unable to bind substrates and a closed conformation conducive to tight 
substrate binding (Fig. 8D, Upper). SBD Is Activated by cpSRP54 in the Soluble Phase. Although 
CD2 does not directly bind substrate proteins, molecular events in this domain regulate substrate 
binding in the neighboring SBD. Intriguingly, CD2 by itself reduces substrate binding in the SBD 
and biases cpSRP43 toward the less active open conformation. Combined with the ability of a 
large number of point mutations in CD2 to hyperactivate cpSRP43 and drive the SBD to the closed 
conformation, these observations suggest the presence of strong evolutionary pressure to maintain 
a substantial population of apo-cpSRP43 in the inactive conformation, i.e., to keep this chaperone 





to be readily turned on by cpSRP54 in the stroma. The C-terminal tail of the cpSRP54 M-domain 
intercalates between the bridging helix and CD2, placing it at an optimal position for regulating 
interdomain interactions (23). In support of this model, we found here that 54M or the 54M peptide 
stimulates the chaperone activity of SBD. A recent study also found that cpSRP54 enhanced 
binding of L18 to cpSRP43 threefold (24). Our observation that the stimulatory effect of 54M is 
largely bypassed in superactive chaperone mutants and becomes more pronounced in defective 
chaperone mutants further indicates that 54M and superactive mutations in CD2 drive the same 
activating conformational change in the SBD. This 54M-driven rearrangement allows cpSRP43 to 
efficiently capture and tightly bind its substrates in the stroma, effectively protecting LHCPs from 
aggregation in the aqueous environment (Fig. 8D, Upper Right). The structural basis of the 
communication between CD2, 54M, and SBD remains a challenging question for future studies. 
Nevertheless, the available data provide intriguing clues. As mutations in the linker bridging the 
SBD and CD2 can lead to gain or loss of function, communication likely involves reorientation of 
CD2 relative to the SBD. This model is consistent with previous small angle X-ray scattering 
(SAXS) analysis (23) and with the observation of enhanced FRET efficiency between dye pairs in 
Ank3 and CD2 on cpSRP54 binding (24). The BH, which connects the ankyrin repeat domain to 
CD2 and whose deletion drives cpSRP43 into the inactive state, provides a prime candidate for 
mediating interdomain communication. Nevertheless, multiple residues in CD1 can sense the 
binding of L18 and 54M, which binds >50 Å away, indicating that substrate and 54M induces 
long-range communications that propagates through the entire length of the SBD.  
 
Bidentate Interactions of Alb3CT Drive Coordinated Substrate Release 
 
At the target membrane, cpSRP43 must facilely release its substrate to the Alb3 translocase. The 
finding that cpSRP43 directly interacts with the stromal domain of Alb3 (25, 27, 30) provides an 
attractive mechanism to couple the release of substrate to its correct localization and imminent 
insertion into membrane. Nevertheless, where and how cpSRP43 interacts with Alb3 has been 
highly controversial, with the ankyrin repeat domain or the chromodomains alternatively proposed 
as Alb3 binding sites (25–27, 29). Here, high-resolution NMR combined with biochemical 
analyses resolved this issue and showed that Alb3CT uses motifs II and IV to make bidentate 
interactions with both the SBD and CD3 of cpSRP43, respectively. As these sites are distinct from 
the 54M binding site (located in CD2), this rationalizes the observation that cpSRP43 can form a 
ternary complex with both cpSRP54 and Alb3CT in the NMR studies here and in previous pull-
down experiments (25). The fact that Alb3CT and cpSRP54 biases cpSRP43 to different 
conformations also explains the anticooperative binding between these two factors (24, 25). Given 
the predominantly electrostatic nature of the interaction between CD3 and Alb3 motif IV, it is 
likely that the acidic patch on CD3 provides the site for initial recruitment of Alb3CT (29), which 
then enables Alb3 motif II to further contact the SBD to induce substrate release. Intriguingly, 
Alb3CT specifically induces the release of substrate TMDs from cpSRP43 without disrupting the 
interaction of the L18 motif with the chaperone. This observation has several important 
implications. First, Alb3CT does not simply reverse the effect of 54M and drive cpSRP43 to the 
completely inactive open conformation. Instead, Alb3CT induces a third, semiopen state of 
cpSRP43 in which its interactions with the L18 and TMDs on substrate protein are uncoupled (Fig. 





membrane, in which the TMDs are first released and could initiate their membrane insertion via 
Alb3, whereas the L18 loop of LHCP remains bound to cpSRP43. Formation of such a 
LHCP•cpSRP•Alb3 release complex at the membrane is consistent with the previous observation 
that cpSRP43 was trapped into high molecular weight species with LHCP on addition of Alb3CT 
(27). In contrast to the current mechanisms in which LHCP is completely released from cpSRP43, 
such a stepwise mechanism would minimize irreversible aggregation of LHCP and abortive 
targeting reactions, providing a more productive route for unloading the membrane protein 




Our work here defines a rigorous framework for the chaperone cycle of cpSRP43 (Fig. 8D). The 
SBD of cpSRP43 samples at least three conformational states: an open state (Upper Left), a closed 
state (Upper Right), and semiopen state that binds tightly to L18 but not the TMDs of LHCP 
(Lower). CD2 biases the SBD to the open state, whereas interaction with cpSRP54 drives cpSRP43 
to the closed state that binds LHCP tightly. When the transit complex is targeted to the thylakoid 
membrane via the interaction of cpSRP54 with cpFtsY, Alb3CT uses motifs II and IV (M2 and 
M4) to make bidentate interactions with SBD and CD3 of cpSRP43, respectively. These 
interactions induce cpSRP43 to a semiopen conformation, triggering the release of the substrate 
TMDs from cpSRP43 and initiating their membrane insertion, whereas the L18 motif remains 
bound to cpSRP43. Ultimate release of L18 from cpSRP43 might be driven by folding of LHCP in 
the membrane and binding of photosynthetic pigments. Although cpSRP43 is dedicated to the 
LHCP family of proteins, it embodies multiple new concepts that have emerged from the recent 
discovery of a wide array of chaperones: (i) the use of protein interaction energy instead of ATPase 
cycles to regulate substrate binding/release, which is found in cyclophilins (34), small heat-shock 
proteins (35–38), and all of the chaperones in the bacterial periplasmic or eukaryotic extracellular 
space; and (ii) the use of conformational flexibility for activation, which was also found in HdeA, 
Hsp33, and Hsp26 (39, 40), and may be a general feature of ATP-independent chaperones. The 
mechanism we describe here for cpSRP43 could facilitate understanding of these conceptually 







Materials and Methods 
 
Protein Expression and Purification. cpSRP43 and Alb3CT mutants were constructed using 
the QuikChange procedure (Stratagene). CD1Ank constructs were deleted residues from 253 to 
266 compared with CD1Ank-BH. In the linker mutants Intein (GSCFNGT) and GSGSG, the 
indicated sequences were inserted between V266 and F267. In mutant 2P, two prolines replaced 
the original linker residues (Q265 and V266). WT and mutant cpSRP43 and LHCP were 
overexpressed and purified as previous described (41). Alb3CT was overexpressed in 
BL21(DE3) cells and purified as previously described (25). 54M peptide 
(QKAPPGTARRKRKAC) was from Eton Bioscience (99% purity). Peptides L11 
(GSFDPLGLADD), L18 (VDPLYPGGSFDPLGLADD), and L11 labeled with HiLyte-Fluor488 
were purchased from AnaSpec (>95% purity). Single cysteine mutants of cpSRP43 and LHCP 
were labeled with fluorescent dyes via maleimide chemistry with 80–90% efficiency. Labeled 
proteins were purified through Sephadex G25 to remove free dye. 
 
Chaperone Activity of cpSRP43. Two types of experiments were used. First, we measured the 
ability of cpSRP43 to prevent LHCP aggregation, as described previously (19, 22). Briefly, urea 
denatured LHCP was diluted into buffer containing varying concentrations of cpSRP43, and 
light scattering at 360 nm was measured over time until equilibrium was reached. The percentage 
of soluble LHCP (% soluble) at equilibrium was plotted as a function of cpSRP43 concentration. 
The data were fit to 
% 𝑠𝑜𝑙𝑢𝑏𝑙𝑒 =  ∆𝐴
𝐿𝐻𝐶𝑃 + 𝑝𝑟𝑜 + 𝐾! − ( 𝐿𝐻𝐶𝑃 + 𝑝𝑟𝑜 + 𝐾!)! − 4[𝐿𝐻𝐶𝑃][𝑝𝑟𝑜]
2[𝐿𝐻𝐶𝑃]  
 
in which [pro] is cpSRP43 concentration, ΔA is the soluble% at saturating cpSRP43 
concentrations, and Kd is the apparent dissociation constant of LHCP interaction with cpSRP43. 
Second, we measured the ability of cpSRP43 to reverse preformed LHCP aggregates. LHCP (1 
µM) was aggregated in buffer for 1 min, followed by addition of 4–5 µM WT or mutant 
cpSRP43, and the clearance of large LHCP aggregates was followed in real time by light 
scattering at 360 nm. 
 
Measurement of L18 Binding. The interaction of L18 with cpSRP43 was assessed by two 
methods. First, binding of cpSRP43 to HiLyte-Fluor488–labeled L11 peptide, which contains the 
minimal interaction sequence in L18, was detected by changes in fluorescence anisotropy of the 
dye. Anisotropy measurements were conducted in buffer D (50 mM KHepes, pH 7.5, 200 mM 
NaCl) on Fluorolog 3–22 (Yobin Yvon), using 100 nM HiLyte-Fluor488–labeled L11 and 
varying concentrations of cpSRP43. The samples were excited at 500 nm, and the fluorescence 
anisotropy was recorded at 527 nm. The data were fitted to 
 
𝐴!"#$ = 𝐴! +  ∆𝐴







in which Aobsd is the observed anisotropy value, A0 is the anisotropy value without cpSRP43, 
ΔA is the change in anisotropy at saturating cpSRP43 concentrations, and Kd is the equilibrium 
dissociation constant for cpSRP43 interaction with L11-HiLyte-Fluor488. To independently 
measure the L18-cpSRP43 interaction without perturbations from the dye, unlabeled L18 peptide 
was used as a competitor for the binding of L11-HiLyte-Fluor488 to cpSRP43; 100 nM L11-
HiLyte-Fluor488 was preincubated with 120 nM cpSRP43 for 5 min, and the complex was 
challenged with an increasing concentration of L18 peptide. Anisotropy values were recorded at 
equilibrium and plotted as a function of [L18]. The data were fit to 
 






in which Aobsd is the observed anisotropy value, A0 is the anisotropy value without L18 
present, ΔA is the change in anisotropy at saturating L18 concentrations, and Kapp is the 
apparent inhibition constant. Alb3CT Binding to cpSRP43. Binding was detected by two 
methods. First, Alb3CT(S371C) was labeled with fluorescein-5′-maleimide (Invitrogen), and 
labeled protein was purified through Sephadex G25 (Sigma) to remove free dye. Binding of 
fluorescein-labeled Alb3CT(S371C) to cpSRP43 was detected by changes in fluorescence 
anisotropy, measured as described for L11 binding except that 200 nM Alb3CT(S371C)-
fluorescein was used instead of L11. Samples were excited at 495 nm, and the fluorescence 
anisotropy was recorded at 512 nm. The data were fit to Eq. 2, with the exception that [Alb3CT] 
replaces [L11]. Second, unlabeled Alb3CT was used as competitors in the interaction of 
cpSRP43 with Alb3CT(S371C)-fluorescein; 200 nM Alb3CT-S371C-fluorescein was 
preincubated with 10 µM cpSRP43 for 5 min, and the complex was chased with increasing 
concentrations of WT or mutant Alb3CT. Fluorescence anisotropy values were recorded at 
equilibrium and plotted as a function of competitor concentration. The data were fit to Eq. 3, 
with the exception that [Alb3CT] replaces [L18]. 
 
Alb3-Induced Substrate Release. LHCP release was evaluated by two methods. First, a soluble 
LHCP•cpSRP43 complex was performed in buffer D using 1 µM LHCP and 5 µM cpSRP43. 
After 1-min incubation, the complex was chased with Alb3CT, and the reaction was monitored 
in real time by light scattering at 360 nm. Second, a single cysteine LHCP mutant 
(C80A,G158C) was labeled with Atto488 maleimide in the middle of L18. A single cysteine 
mutant of cpSRP43 (C175A-C297) was labeled with TMR-5-maleimide (Invitrogen). Labeled 
LHCP (50 nM) and cpSRP43 (2 µM) were preincubated for 5 min in buffer D with 0.1 mg/mL 
BSA, followed by addition of 5 µM Alb3CT. Fluorescence was monitored on a Fluorolog 3–22 
spectrofluorometer (JobinYvon) using an excitation wavelength of 505 nm and emission 
wavelength of 525 nm. A control release reaction was performed using unlabeled cpSRP43 to 
obtain the intensity for the donor sample (ID). FRET efficiency was calculated as 
 









in which IDA is the fluorescence intensity of donor in the presence of acceptor-labeled cpSRP43. 
 
NMR Spectroscopy. Multidimensional NMR spectra were recorded on Bruker Advance 
spectrometers operating at 800 and 900 MHz. All NMR spectra were acquired at 17 °C using 
2H, 15N-labeled or 2H, 15N, 13C-labeled protein (∼0.2 mM) in NMR buffer containing 10% 
(vol/vol) D2O at pH 6.5. Titration experiments were performed by serial addition of unlabeled 
ligands into the NMR sample containing 2H, 15N-labeled cpSRP43. NMR data were processed 
with NMRPipe (42) and analyzed with NMRView Java (43). Details on NMR sample 
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SI Materials and Methods 
 
Protein Production and Purification for NMR. Isotope-labeled full-length cpSRP43 and 
CD1Ank-BH were overexpressed in BL21(DE3) cells at 37 °C in M9 D2O media supplemented 
with 15NH4SO4 and 12C or 13C-glucose. Protein expression was induced at OD600 = 0.7 by 
addition of 1 mM IPTG for 15 h. Isotope-labeled cpSRP43 and CD1Ank-BH were purified using 
the same protocol as unlabeled cpSRP43. Proteins were exchanged into NMR buffer (50 mM 
phosphate, 150 mM NaCl, pH 6.5) using a PD MidiTrap G-25 column (GE Healthcare). 
 
Assignment of cpSRP43 Backbone. Triple labeled (2H, 15N, 13C) cpSRP43 and CD1Ank-BH 
(∼0.8 mM) were prepared in NMR buffer containing 10% (vol/vol) D2O. Backbone resonance 
assignments were made using 3D TROSY-HNCA, TROSY-HN(CO)CA, TROSY-HNCACB, 
and TROSY-HN(CO)CACB spectra (44, 45). A total of 252 of 323 nonproline backbone 
residues were assigned using RunAbout in NMRview java. Many of the cross-peaks associated 
with CD2 are weak, and only a subset (residues 278–287) could be assigned from the triple 
resonance spectra. Assignments for additional CD2 residues (F267, D273, I275, E277, L288, 
V289, W291, D293, G294, W299, V300, G302, D308, V309, and K311) were made by 
transferring published assignments for the isolated CD2 domain (33). 
 
Characterization of the Oligomeric State of cpSRP43. The oligomeric state of cpSRP43 was 
assessed by two methods. First, cpSRP43 in the presence or absence of equal molar HiLyte-
Fluor488–labeled L11 peptide were analyzed by size exclusion chromatography using Superdex 
200 column (GE Healthcare). The column was equilibrated in 50 mM KHepes, pH 7.5, with 
either 200 mM or 50 mM NaCl. The protein elution profile was confirmed by SDS/PAGE, and 
the molecular mass on the column was further calibrated using the LMW kit (GE Healthcare). 
Second, velocity sedimentation-type analytical ultracentrifugation was performed using Optima 
XL-I (Beckman Coulter) with an absorbance optical detection system (280 nm). The sample was 
spun at 50,000 rpm at 20 °C with 7 µM of cpSRP43 alone and in complex with equal molar of 
HiLyte-Fluor488–labeled L11 peptide or cpSRP54M. Buffer viscosity, protein partial specific 
volumes, and density were calculated using the SEDNTERP (46). The observed sedimentation 
data were fitted to a single component system by using the SEDFIT software (47), and the 
sedimentation coefficient distribution was extracted from the fitting. 
 
Fig. S1. Sequence alignment of cpSRP43 CD1, CD2, CD3, Polycomb (Pc), and heterochromatin protein 1 (HP1). Green highlights 





chromodomains. Black asterisks denote aromatic cage residues involved in 54M binding (23). Secondary structure information is labeled 
above the sequence highlighting β-sheet (β1, β2, β3) and α-helix (α1). 
 
 
Fig. S2. CpSRP43 is active as a monomer. (A) WT (red) and superactive intein-cpSRP43 (cyan) runs as a monomer on Superdex 200 
column with buffer containing 200 mM NaCl. (B) The complex of WT cpSRP43 and HiLyte-Fluor488–labeled L11 peptide (blue) was 
eluted as a 1:1 complex. (C) At lower ionic strength (50 mM NaCl), cpSRP43 exhibits oligomeric forms (red), but L11 binding shifts 
cpSRP43 to a lower molecular weight complex (blue). (D–F) Sedimentation coefficient distributions calculated from a velocity 
sedimentation experiment of cpSRP43 alone (D), cpSRP43 with HiLyte-Fluor488–labeled L11 peptide (E), and cpSRP43 with cpSRP54M 
(F) using buffer containing 200 mMNaCl. The experimental molecular mass is close to the predicted values of cpSRP43 and cpSRP54M 











Fig. S3. Assignments of the cpSRP43 spectra. (A) 800 MHz 1H-15N TROSY spectrum of full-length 15N, 13C, 2H-labeled cpSRP43 is 
shown with the assigned residues indicated. The central area of the spectrum is enlarged for clarity. (B) Assigned residues are 
highlighted in red in the cpSRP43 sequence. 
 
 
Fig. S4. Pairs of component cross-peaks in CD1 arise from the same amino acids. (Upper) Component cross-peaks of residues Ser92 (A) 
and Ala95 (B) in the TROSY spectrum of 2H, 15N, 13C-labeled CD1Ank-BH. (Lower) Strips from the HNCACB and HN(CO)CACB 
spectra of 15N, 13C, 2H-labeled CD1Ank-BH for the two component peaks of S92 and A95. For each residue, the two component peaks 
have connectivities to identical Cα and Cβ chemical shifts for residues i and i-1, indicating that they arise from the same amino acid. The 







Fig. S5. The conformation of cpSRP43 is regulated by binding partners. (A–C) Titration of the L18 peptide (A), 54M peptide (B), and 
Alb3CT (C) into the 2H,15N-labeled cpSRP43 during the TROSY experiment. Component cross-peaks are shown for Ser92. (D–F) 







Fig. S6. Quantification of the relative intensities of component cross peaks for 12 residues in various chaperone constructs and with 
various ligands bound.–BH, CD1Ank fragment; +Alb3, full-length cpSRP43 + Alb3CT; FL, full-length cpSRP43; +BH, CD1Ank-BH 







Fig. S7. Summary of the effect of Alb3CT on cross-peak intensities in the 1H-15N TROSY spectra of full-length cpSRP43 (A) and the 
CD1Ank-BH fragment (B). The intensities of each cross-peak in the presence and absence of Alb3CT [I(+Alb3CT) and I(–Alb3CT), 
respectively] were quantified and normalized to those of residues 1–63, a highly unstructured region whose intensities were unaffected by 
any binding partners, and their ratios were plotted. The gray bars denote unassigned residues (including all of the prolines), and the 
dashed lines show the cutoff where the peak is broadened ≥70%. (C) Structural model for full-length cpSRP43 (19). Dark red highlights 
residues whose cross-peaks are broadened >70% (from A) on binding to Alb3CT. Green highlights Tyr204 that binds L18. 
 
 
Fig. S8. (A) Alb3CT induces dose-dependent release of LHCP TMDs from cpSRP43, performed as outlined in Fig. 5F and described in 
Materials and Methods. Red, orange, green, blue, and black denote data obtained with 0, 0.625, 1.25, 2.5, and 5.0 µM Alb3CT, 





the positions of the FRET probes. Residue G158 in the L18 motif of LHCP (green) was mutated to cysteine and labeled with Atto488 











Fig. S9. Effects of 54M binding on the intensity of G264 (in BH). (A) Region of the TROSY spectrum of 2H, 15N-labeled cpSRP43 
showing the effects of increasing concentrations of the 54M peptide on the G264 cross-peaks corresponding to unbound and 54M-bound 
cpSRP43 (labeled as peak 1 and peak 2, respectively). (B) Quantification of the relative intensities for the 54M-bound peak (peak 2) for 
G264. The line is a fit of the data to Eq. 1. 
 
Additional Supplementary Material (Unpublished, performed by C.Z.M.) 
 
Linker Mutant Prevention Data. The full linker mutant binding data is shown in Supplementary 
Figure 1. As this figure shows, changes in binding between the linker mutants are subtle. From this 
data, wild-type cpSRP43 has a Kd of 177 nM, the most flexible mutant, (GS)5, has a Kd of 100 
nM, the least flexible mutant, 2P, has a Kd of 414 nM, the deltalinker mutant has a Kd of 211 nM, 
and 2G has a Kd of 186 nM.  
 
Additional Supplementary Figure 1. Full linker mutant characterization from LHCP aggregation/prevention experiments. 
Linker Mutant Disaggregation Data. The full linker mutant disaggregation data is shown in 
Supplementary Figure 2. From this data, a correlation can be observed between linker mutant 
flexibility and disaggregation rate, namely that the more flexible linker, (GS)5, has a faster rate and 
the more rigid linker, 2P, has a slower rate. Similarly, end point analysis shows this same 
relationship between liker mutant flexibility and percent disaggregated at the end of the 




























(a) (b)  
Additional Supplementary Figure 2. Full linker mutant characterization from LHCP disaggregation experiments. (a) A correlation can be 
observed between linker mutant flexibility and disaggregation rate. (b) Likewise, end point analysis shows a relationship between linker 
mutant flexibility and percent disaggregated at the end of the disaggregation experiment. 
 
Supplementary Figure 3. Summary of prevention and disaggregation linker mutant data for defective 2P mutant and superactive (GS)5 
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The chloroplast signal recognition particle component 43, cpSRP43, acts as an ATP-independent 
chaperone to the light harvesting chlorophyll-binding proteins (LHCP). We have found that 
cpSRP43 interacts with substrate via an unfolded to folded transition. The substrate binding 
domain, and particularly the bridging helix region, of cpSRP43 is partially unfolded in the apo 
protein. Upon interaction with co-chaperone cpSRP54, cpSRP43 shows mild structuring, and upon 
interaction with both cpSRP54 and LHCP, cpSRP43 shows significant helix formation from an 
otherwise unstructured state. These results are consistent with NMR data that suggests structuring 
of cpSRP43 upon interaction with cpSRP54 and LHCP. Overall this work represents a novel 
characterization of the cpSRP43 structural state. Further this unstructured to structured transition 










Proper protein folding and localization are critical for cellular protein homeostasis which is acutely 
challenged by the post-translational targeting of integral membrane proteins. Before arrival at the 
target membrane, nascent membrane proteins are highly prone to aggregation in the cytosol and 
other aqueous cellular compartments. Thus, effective molecular chaperones or chaperone networks 
are required to minimize improper exposure of the transmembrane domains (TMDs) on newly 









A bridging helix mediates conformational change in cpSRP43. Using a light scattering assay 
and single cysteine mutants along the solvent-exposed surface of cpSRP43’s bridging helix (BH), 
we found that the BH is very sensitive to mutation and further that defective or even dead mutants 
can be rescued with cpSRP54M-domain. The mutations made along the BH are highlighted in 
Figure 1A with neutral mutants in green, defective mutants in orange, and the single dead mutant 
I259C in red. This dead mutant was further studied using the light scattering assay (Figure 1B). It 
was found that in the presence of 54M-domain, aggregation was not observed in the presence of 
I259C cpSRP43 mutant with LHCP. This could have been due either to 54M directly binding 
substrate (although previous work has shown that cpSRP54 alone has no chaperone activity) or 
through 54M exerting a conformational change in I259C cpSRP43, allowing this otherwise dead 
mutant to become active. Using 54M peptide, a short fragment of cpSRP54M known to bind to 
cpSRP43, we observed similar rescue of LHCP as was seen in the 54M-domain case, suggesting 
that 54M acts through conformational change in cpSRP43 rather than directly binding substrate. 
As a final control, we utilized a cpSRP54M-domain mutant in which only the portion of 54M that 
binds cpSRP43 is mutated (deltaRRKRK 54M); there was no prevention of aggregation observed 
with cpSRP43 I259C and the deltaRRKRK 54M mutant suggesting that 54M binding to cpSRP43 
is necessary for chaperone activity, further corroborating cpSRP43’s role as chaperone and 54M’s 
role as a modulator of conformational change in cpSRP43. The same rescue of activity with 54M-
domain was observed for defective cpSRP43 mutant E256C as seen in Figure 1C. Further, for all 
defective BH mutants, 54M was able to rescue chaperone activity (Fig 1D and 1E, respectively). 
One possibility could have been that the BH was directly interacting with CD2 and that these 
mutations interfered with those reactions and 54M was then able to reestablish them. However, 
deleting CD2CD3 from cpSRP43 to arrive at the minimal substrate binding domain (SBD, see 
Liang et al. PNAS 2016) and inserting each of the defective mutants into this construct did not 
result in reversal of the defective phenotype, indicating that BH-CD2 interactions alone do not 
account for the conformational changes observed in the bridging helix mutants. 
 
EPR indicates that the nature of conformational change in cpSRP43 is likely an unfolded-
folded transition. EPR was performed using neutral mutants throughout cpSRP43’s substrate 
binding domain (SBD) in the presence and absence of cpSRP54M-domain and LHCP substrate. 
The neutral mutants are indicated in Figure 2A (purple) and their chaperone activity is given in 
Figure 2B; all mutants used for EPR had chaperone activity within threefold of cysteineless WT. 
EPR spectra of all mutants in the apo form (black), plus 54M-domain form (blue), and plus 54M-
domain and LHCP (green) are given in Figure 2C. From these spectra, central linewidth (1/deltaH, 
Figure 2D) and mobility (intensity of mobile/intensity of immobile peak, Figure 2E) analyses were 
performed to compare relative mobility of each of the residues studied. These data, particularly in 
the bridging helix region (mutants I253C and G264C), indicate a potential shift from a partially 
unstructured state in the apo form to a somewhat more structured state with the addition of a 54M-
domain and a fully structured state in the presence of 54M-domain and LHCP. Based on 





expect to be a well-structured alpha-helix, goes from an unstructured state to an alpha-helical one 
going from apo to with 54M-domain and LHCP forms. This same trend is observed in the mobility 
analysis in Figure 2E. 
 
HDX further corroborates the unfolded-folded model of cpSRP43 conformational change. 
Protection patterns obtained through hydrogen-deuterium exchange further indicate the role of 
conformational change in cpSRP43 binding. cpSRP43 in various backbones and with various 
ligands was subjected to HDX and perturbation maps were generated to study the protection 
patterns of cpSRP43 under these various conditions. The addition of either substrate (Lhcb5) or 
cpSRP54M-domain causes structuring in Ank2, Ank3, and the BH of cpSRP43 (Figure 3A and 3C, 
respectively); this result agrees with the EPR results, suggesting that binding of 54M-domain and 







Through EPR, HDX, and NMR we have demonstrated that cpSRP43 undergoes a structural 
transition upon substrate binding and moreover that this transition likely involves going from a 
partially unstructured to structured state. This represents a novel characterization of cpSRP43 
structural state that accounts for its ATP-independence. That is, a structural transition is coupled to 
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Materials and Methods 
 
Protein Expression and Purification. Single cysteine mutants of Lhcb5 and cpSRP43 were 
constructed using the QuikChange Mutagenesis procedure (Stratagene) according to 
manufacturer’s instructions. WT and mutant cpSRP43, LHCP, and wildtype and mutant Lhcb5 
were overexpressed and purified as previously described (Jaru-Ampornpan Mol Biol Cell 2007). 
 
Chaperone Activity of cpSRP43. The ability of cpSRP43 to prevent LHCP aggregation was 
measured as described previously (Jaru-Ampornpan et al. NSMB 2010, Jaru-Ampornpan et al. 
JBC 2013). Aggregates were removed via ultracentrifugation in a TLA-100 rotor (Beckman 
Coulter) at 100,000 rpm for 30 min at 4 °C prior to the experiment. Light scattering experiments 
were performed by addition of 3 µL of 50 µM LHCP denatured 8M urea to 150 µL buffer D (50 
mM KHEPES, pH 7.5 and 200 mM NaCl) or 2.5 µM cpSRP43 in buffer D. Light scattering was 
monitored at 360 nm on a UV-Vis spectrometer (Beckman Coulter) over time until equilibrium 
was reached. The percentage of soluble LHCP (% soluble) at equilibrium was plotted for each 
single-cysteine cpSRP43 mutant. 
 
Site-directed spin labeling and EPR measurements. Spin labeling reactions were performed in 50 
mM Hepes, pH 7.5, 200 mM NaCl. Reduced and degasses single cysteine mutants of cpSRP43 
were labeled with five- to tenfold molar excess of MTSSL (Toronto Research Chemicals) at room 
temperature in the dark for 2-3 h. Excess MTSSL was removed by gel filtration. EPR spectra were 
acquired using a 9.4-GHz (X-band) EMX EPR spectrometer (Bruker) equipped with an ER 
4119HS cavity at room temperature. The concentrations of spin-labeled samples were 30-100 uM 
cpSRP43. 5-30 scans were accumulated and averaged using microwave power of 5 mW with 
modulation amplitude set at 1 gauss and a magnetic field sweep width of 100 gauss. Less than 2% 
background labeling was observed; background subtraction was therefore not necessary. 
 
Hydrogen-deuterium exchange mass spectrometry. Approximately 10 uM protein used for each 
injection. For each differential HDX experiment, 120 uL of apo and 120 uL of bound sample used. 
Each HDX experiment consisted of 7 time points (0, 10, 30, 60, 300, 900, and 3600 seconds) in 3 
replicates. 5 uL of each protein sample is diluted with 20 uL H2O/D2O HDX buffer for each 
injection (time point). This 25 uL protein sample is quenched with 25 uL buffer and then injected 
for LC-MS. The spectra (apo versus bound) are then analyzed via HDX work bench software to 








Table 1. K1/2 and Kd values for binding of LHCP to individual cpSRP43 mutants obtained from light scattering 
data with and without cpSRP54M. All cpSRP43 mutants shown in this table are derived from cysteine-less 
cpSRP43 (denoted as WT). 1 µM LHCP was used for all light scattering experiments and 1:1 cpSRP43:54M 





Construct -54M K1/2 
(nM) 
% Soluble at 
Saturation 
Hill Coefficient R value +54M Kd  
(nM) 
WT 2100 85% 2.1 1.0 50 
R252C 6800 88% 2.3 0.99 840 
E256C 8400 80% 4.6 1.0 180 
I259C No binding No binding No binding No binding 980 










Figure 1. The bridging helix mediates the unfolded-folded conformational transition in cpSRP43. (A) Structure of cpSRP43 highlighting the 
residues in the bridging helix that were studied. (B) Chaperone activity spectra in the absence (green) and presence of cpSRP43-I259C 
mutant (black), and mutant plus 54M domain (light blue), 54M peptide (dark blue), and deltaRRKRK mutant (orange). This figure 
demonstrates that 54M induces a conformational change that allows cpSRP43 to perform its chaperone activity rather than 54M directly 
chaperoning LHCP. If 54M were acting as a chaperone we would not expect 54M peptide to have chaperone activity yet we see here that 
aggregation is prevented in the presence of the I259C cpSRP43 mutant and 54M peptide, implying that 54M induces a conformational 
change in cpSRP43. The deltaRRKRK 54M mutant does not bind to cpSRP43 and the observation that addition of this mutant does not 
restore chaperone activity is an indication that 54M must bind to cpSRP43 to induce chaperone activity. (C) Chaperone activity spectra in 
the absence (green) and presence of cysteineless cpSRP43-E256C mutant (black), and mutant plus 54M domain (light blue). (D) Activity of 
defective BH mutants in the absence of cpSRP54M-domain at 2.5 uM (light gray) and 5.0 uM (dark gray) concentrations of cpSRP43. (E) 
Activity of defective BH mutants in the presence of cpSRP54M-domain at 2.5 uM (purple) and 5.0 uM (red) concentrations of cpSRP43. (F) 











Figure 2. The component cross peaks of Ser92 in cpSRP43 are sensitive to urea unfolding. (A) Titration of the urea into the 2H, 15N-labeled 
full-length cpSRP43 during the TROSY experiment. Component cross peaks are shown for Ser92. (B) Quantification of the relative intensity 
of the component cross peaks, inactive (red) and active (blue), from the data in parts (A) are shown. (C) The relative intensities of the cross 
peaks corresponding to the inactive chaperone conformation are enhanced by urea (red bars) as compare to without urea (blue bar). Data 
are shown for indicated residues in 2H, 15N-labeled full length cpSRP43. Relative intensities were determined from cross peak heights. 
 
 
Figure 3. HDX perturbation results mapped onto cpSRP43 structure. (A) Full length cpSRP43 with L18. As indicated in the perturbation 
key, darker blue indicates more protection, whereas redder indicates deprotection, and gray indicates no change from the apo to the plus L18 
state. (B) Protection pattern change from apo full-length cpSRP43 to full-length cpSRP43 with 54M (left). (C) Protection pattern change 












Figure 4. EPR analysis indicates an unstructured-structured transition in cpSRP43 upon interaction with cpSRP54M-domain and LHCP. 
(A) Structure of cpSRP43 highlighting sites of structural transition. (B) Chaperone activity data showing that all mutants used for EPR were 
neutral mutants within threefold activity of the cysteineless WT cpSRP43. (C) Representative EPR spectra of cpSRP43 alone (black) and 
with 54M domain (red) and 54M domain plus LHCP (green). (D) Linewidth analysis of EPR spectra show that cpSRP43 in the apo form 
appears to be partially unstructured (black) but shows mild structuring upon addition of cpSRP54 M domain (red) and significant 
structuring upon addition of cpSRP54 M domain and LHCP (green).  
 
 
Figure 5. L18 binding induces secondary structure perturbation in ankyrin repeat region. (A and B) Secondary shift analysis of Calpha carbon 
shows the presence of L18 (A) induces more helical structure in the first helix of Ank3 as compared to the absence of L18 (B). Dashed line is 
shown for the 2.8 ppm cutoff and yellow bar is shown for unassigned/ambiguous region. (C) Calpha carbon chemical shifts difference plot 
suggests L18 induced major structure perturbation in the first helix of Ank3 and some minor changes in Ank2. Dashed line is shown for the 
0.8 ppm cutoff and yellow bar is shown for unassigned/ambiguous region. (D) NBD domain of cpSRP43 structure (PDB 3DEO) highlights the 









Figure 6. Final model of cpSRP43 structural transition. cpSRP43 exhibits spring-like motions going from a partially unstructured to 










Supplementary Figure 1. Full HDX protection maps. (A) Perturbation map of full length WT cpSRP43 with L18 peptide. (B) Perturbation 







Supplementary Figure 2. Full HDX protection maps. (C) Perturbation map of full length WT cpSRP43 vs superactive intein cpSRP43. (D) 
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Membrane protein and cpSRP43 co-expression 
 
Membrane proteins are an important class of proteins whose study has been impeded by lacking 
overexpression yields. Approximately, 20-30% of genes encode membrane proteins and about 
50% of drug targets are membrane proteins.1,2,3 Although E. coli is the most widely used 
expression host, membrane protein yields are often insufficient for structural and functional 
studies.1 Overexpression of both prokaryotic and eukaryotic membrane proteins leads to saturation 
of the Sec translocon which leads to: i) protein misfolding/aggregation in cytoplasm, ii) impaired 
respiration, and iii) activation of the Arc response, which leads to inefficient ATP production and 
the formation of acetate.2,3  
 
Strategies to improve membrane protein expression have included engineering E coli strains, using 
organisms other than E. coli, engineering/selecting for membrane protein variants that show better 
expression, co-expression with chaperones, and expression using cell-free systems.1 Although each 
of these strategies has shown some success, no strategy has yet been shown to be completely 
generalizable for broad membrane protein expression. Using our knowledge of the cpSRP43 
chaperone, we seek to improve membrane protein yield by co-expressing membrane proteins with 
cpSRP43. Unlike other ATP-dependent disaggregases whose activity can be taxing on a cell’s 
resources, cpSRP43 can act through recognition of an L18 fusion and promiscuous hydrophobic 
contacts with membrane proteins of interest. Our hypothesis is that cpSRP43 can help improve 
membrane protein expression by preventing the aggregation of membrane proteins as they are 
produced. Further, we theorize that cpSRP43 will help to keep membrane proteins in functional 
form by keeping them from going into inclusion bodies where helical bundle membrane proteins 
are rarely found to be functional.18 Various pieces of evidence have hinted at cpSRP43’s potential 
ability to chaperone non-native substrates, particularly data involving LHCP transmembrane 
domain (TM) swap mutants and preliminary studies of cpSRP43 with Aβ40. 
 
TM Swap Mutant Studies. LHCP consists of three transmembrane domains, an L18 motif, and 
N and C terminal regions, as shown in Figure 1.4,5 
 
 
Figure 1. Light-harvesting, chlorophyll-binding protein (LHCP) organization (4,5). LHCP consists of three transmembrane domains (TM1, 
TM2, and TM3), an L18 motif, and N-and C-terminal portions (4,5). 
 
To determine what interactions were important between cpSRP43 and substrate, the TMs of native 
LHCP were systematically exchanged with TMs from other membrane proteins, namely SERP1 
and cytochrome B5. The SERP1 TM was swapped with LHCP TM2 and on another mutant it was 
swapped with LHCP TM3.4 Likewise, a mutant was made in which cytochrome B5 was swapped 
with LHCP TM3.4 Additionally, a truncation was made in which TM1 was removed from LHCP 
leaving only TM2, TM3, L18, and N- and C-terminal fragments.4 From this truncated LHCP, 






construct with none of the native LHCP TM’s but with the same N-terminal, C-terminal, and L18 
scaffold of LHCP as shown in Figure 2.4,5 
 
Figure 2. LHCP mutant in which all native LHCP TM’s have been replaced.4,5 TM1 has been deleted; TM2 has been swapped for Cyb5, and 
TM3 has been swapped for Serp1. However, the L18 portion and scaffold (that is N-and C-terminal portions) are all the same as the native 
LHCP substrate. 
 
Using this LHCP mutant with no native TM’s, cpSRP43 was found to have comparable 
disaggregation activity and a modestly higher disaggregation rate than when using wild-type 
LHCP (Figure 3).4,5 These results support the model that cpSRP43 interacts with its substrates in 
two ways: 1) through a specific L18 interaction and 2) through promiscuous hydrophobic 
interactions.  
 
Figure 3. Disaggregation data for LHCP deltaTM1 in which TM2 has been swapped with Cyb5 and TM3 has been swapped with Serp1.2,21 
This mutant substrate shows comparable disaggregation properties to wild-type LHCP with a modestly faster disaggregation rate. cpSRP43 
in these experiments is at a concentration of 5 uM. 
 
To further test the capabilities of cpSRP43 to chaperone non-native substrates we attempted to 
express SERP1 fused to L18 in order to study this substrate and not just the SERP1 TM in the 
LHCP scaffold, as was studied for the TM swap mutants. However, the SERP1 protein could not 
be expressed in sufficient quantities to study.6 To overcome this problem, we sought to utilize 
cpSRP43’s dual interactions with substrates to improve membrane protein expression. We 
hypothesized that by fusing the L18 motif to membrane proteins, cpSRP43 could chaperone them 
in E. coli cells through specific L18 recognition and promiscuous hydrophobic interactions. This 
chaperone activity would be expected to be generalizable to various membrane proteins, given a 
positioning of the L18 motif in such a way that it is exposed on the aggregate surface for cpSRP43 







With this knowledge in mind, we aimed to use cpSRP43 as a means of increasing membrane 
protein expression. We began these experiments first by optimizing cpSRP43 expression in E. coli. 
We then went on to test cpSRP43’s activity by looking at co-expression with various membrane 
protein substrates. In doing so, we looked at factors such as temperature dependence of expression 
and L18 dependence of substrates. Because of cpSRP43’s important interaction with L18 in 
LHCP, one would expect that this interaction is necessary for increased expression of membrane 
protein substrates. Finally, we looked at fractionation to determine the location of the expressed 
membrane protein substrates. It is known that membrane proteins that end up in inclusion bodies 
are rarely functional proteins.1 Therefore, in our strategy to increase membrane protein co-
expression we aim to improve localization to the membrane in order to get functional membrane 
proteins. Using our various expression, L18 dependence, and fractionation data we are able to 









Optimization of cpSRP43 expression for co-expression experiments. In trying to increase 
membrane protein expression, it was first necessary to optimize the expression of the cpSRP43 
chaperone. For our initial studies, Serp1 was our model substrate. The results of this optimization 
are summarized in Figure 4. Our initial construct had both a His6 tag on cpSRP43 and on Serp1. 
However, having a His6 tag on both cpSRP43 and on the substrate made analysis ambiguous 
because it turned out that cpSRP43 had degradation products of similar molecular weight to the 
substrates of interest. Another major issue was that baseline cpSRP43 expression was low. We 
looked at different vectors, namely pACYCDuet, pQE and pET and ultimately used pQE for co-
expression experiments because pQE was what was used in the past to express and purify 
cpSRP43 alone.1 Despite this change, cpSRP43 expression was still relatively low.  
We next turned to cell type as a means of optimizing expression. Comparing BL21-DE3*, 
Rosetta, and BL21-CodonPlus-DE3-RIL cells, we found dramatically increased expression with 
BL21-CodonPlus cells. To overcome the ambiguity of having both cpSRP43 and substrate being 
His6-tagged, we let the substrate remain His6-tagged (for easy detection by Western blot and 
ultimately for purification) and then FLAG-tagged cpSRP43. However, the switch from a His6-tag 
to a FLAG-tag on cpSRP43 dramatically diminished expression. Comparing cpSRP43 with no tag, 
FLAG, Strep, and His6 tags, we found that N-terminally His6-tagged cpSRP43 had the best 
expression. Because we found that the His6 tag was needed for high cpSRP43 yield, we ultimately 
switched the tag on the substrate to a FLAG tag (for detection via Western blot). Thus the 
conditions we ultimately settled upon after optimization were BL21-CodonPlus-DE3-RIL cells, 
pQE-80L vector, His6-cpSRP43, and FLAG-substrate, as summarized in Figure 4. The final 
construction of the co-expression plasmid is shown in Figure 5. 
 
Figure 4. Optimization of cell type, vector, and tags for cpSRP43 expression. Within each portion of the chart is a gel showing pre-induction 
(-IPTG, left lane) and post-induction (+IPTG, right lane) conditions for cpSRP43 expression using various cell types, vectors, and tags on 
cpSRP43. The best conditions for cpSRP43 expression are circled in green: BL21-CodonPlus-DE3-RIL cells, a pQE-80L plasmid, and a His6 






Figure 5. Schematic of pQE-80L plasmid containing the co-expression construction. cpSRP43 is N-terminally tagged with His6 and the 
substrate is N-terminally tagged with FLAG and C-terminally tagged with L18. 
 
Substrate scope of co-expression of cpSRP43 with membrane proteins. The substrates tested 
were a combination of tail-anchored proteins and two transmembrane domain proteins. These 
substrates are summarized schematically in Figure 6. The initial substrates used for optimization 
of cpSRP43 expression conditions were Sec61B, a subunit of the protein transolocation 
machinery in the ER, Serp1, a stress-associated ER protein, and Lep1, an E. coli protein known 
as leader peptidase that is involved in removing amino-terminal peptides from exported proteins 
(Figure 6a). From these initial substrates, we expanded our scope to various tail-anchored 
membrane proteins (Figure 6b) including cytochrome b5 (Cyb5), an electron donor involved in 
lipid biosynthesis, SNARE proteins Sec22, Use1, and Bos1, and finally Scs2, an integral ER 
protein involved in phospholipid metabolism. Our last group of preliminary test substrates 
consists of two TM swap mutants of the large mechanosensitive channel (MscL) derived from S. 
aureus and E. coli (Figure 6c). These substrates, numbered 27 and 51, were C-terminally tagged 


















Figure 6. Preliminary membrane protein substrates. (a) First set of substrates developed while optimizing cpSRP43 expression conditions. 
These initial substrates include two tail-anchored proteins, Sec61B and Serp1, and a 2 TM bacterial substrate, Lep1. (b) Schematic of various 
tail-anchored proteins which include Cyb5 and Sec22 (pictured) as well as Use1, Scs2, and Bos1 (not pictured but following an analogous 
scheme). (c) Large mechanosensitive channel (MscL) constructs made by swapping components from S. aureus MscL and E. coli. The parent 
constructs are shown for S. aureus (peach) and E. coli (blue). The swapped mutants are labeled 27 and 51 and were tagged with the L18 
motif. 
 
Preliminary screening of these membrane protein substrates has shown promise for 
improved membrane protein expression with cpSRP43 co-expression. Promising substrates include 
Serp1, Sec61B, Sec22, Scs2, and Use1. The expression of each of these substrates with and 
without cpSRP43 co-expression is shown in Figures 7 and 8. All substrates were grown at 37˚C, 
250 rpm and induced for four hours with 1.0mM IPTG at an OD600~0.4-0.6. In each figure, a 
Coomassie-stained gel confirms co-expression of cpSRP43 and an anti-FLAG western blot shows 
expression of the membrane protein of interest. Each western blot is then quantified to show the 
relative levels of membrane protein expression with and without cpSRP43. The quantifications are 
only a relative comparison and are not standardized to protein concentration. The relative protein 
expression levels are quantified such that 100% represents the highest protein expression level on 
the gel and other percentages represent protein expression relative to the 100% case. In this way 
protein expression can be compared directly between substrates with and without cpSRP43.  
Unsuccessful substrates include Cyb5 and MscL27 which are not expressed within the 
level of western blot sensitivity either in the with or without cpSRP43 case. Intriguingly, in the 
case of MscL27, cpSRP43 expression is not seen on the Coomassie gel (Figure 7a). Unlike the 
other tail-anchored substrates, MscL27 forms a multimeric complex and it is possible that in trying 
to chaperone MscL27, cpSRP43 is degraded along with MscL27 if this substrate unable to form a 
complex as it is expressed. Lep1 likewise does not co-express with cpSRP43 and shows the same 
phenomenon as MscL27 in that cpSRP43 expression is not observed (data not shown). Future 
experiments such as pulse-chase analysis to determine both cpSRP43 and substrate degradation 
need to be performed in order to assess whether cpSRP43 is being degraded in its attempt to 






Figure 7. Co-expression of cpSRP43 with Serp1, Sec61B, and MscL27. The Coomassie-stained gel (a, left) shows cpSRP43 expression. The 
anti-FLAG western blot (b, right) shows the expression of Serp1, Sec61B, and MsCl27 with and without cpSRP43. 
 
Figure  8. Quantification of co-expression anti-FLAG Western blot. Lanes 1 and 2 show quantification of only the Serp1 band found at the 
expected molecular weight of approximately 12 kDa. There is significantly more expression with cpSRP43 than with Serp1 alone. Lanes 3 
and 4 show quantification of all bands combined in the Serp1 western blot, potentially representing dimers or aggregates of this protein. 
Including all bands, co-expression with cpSRP43 is still significantly improved relative to Serp1 alone. For Sec61B, shown in Lanes 5 and 6, 






Figure 9. Coexpression of cpSRP43 with Cyb5, Sec22, MscL27, Scs2, Use1, and Bos1. cpSRP43 overexpression is seen for Cyb5, Sec22, Scs2, 
Use1, and Bos1 (prominent cpSRP43 band at ~38kDa) in all cases except for MscL27. MscL27 has the same vector construction and 
cpSRP43 gene as all of the other co-expression plasmids and underwent the same induction conditions. 
 
Figure 10. Anti-FLAG western blot and quantification of expression of various membrane proteins. Only substrates showing detectable band 
were quantified. Sec22, Scs2, and Use1 showed significantly improved expression with cpSRP43 co-expression. All bands were quantified 
relative the most prominent band, the Sec22 with cpSRP43 band, which has been set to 100% as a reference point. 
 
Overall, these preliminary screens are promising for the use of cpSRP43 as a means of improving 
membrane protein co-expression. Additionally, as described in greater detail previously, structure-
function cpSRP43 mutant studies have led to a superactive cpSRP43 mutant with improved 
binding and disaggregation activity that can potentially be used to improve the expression of 
substrates that did not show initial promise with wild-type cpSRP43 co-expression. 
 
Dependence of Membrane Protein Expression on Growth Temperature. Initial studies of 





difference between growth at 25˚C versus 37˚C as shown in Figure 11. However, it must be 
noted that these studies were conducted using an early vector construction of His6-cpSRP43 and 
His6-substrate in BL21DE3* cells, which was later optimized as described in the cpSRP43 
expression optimization section. Therefore, although these experiments show little variation with 
growth at 25˚C versus 37˚C, the conditions must be repeated with the new optimization 
conditions (His6-cpSRP43 and FLAG-substrate, BL21-CodonPlus-DE3-RIL cells) and test 
substrates. It is interesting to note that under these pre-optimized conditions, there was very little 
expression of Serp1 in the absence of cpSRP43, whereas in the optimized conditions Serp1 alone 
expression is improved. This change in baseline Serp1 alone expression is discussed in more 
detail in the Supplementary Information section. 
 
Figure 11. Expression of Serp with L18-tag, L11-tag, and no tag. (a, left) Anti-His6 western blot showing cpSRP43 (blue arrow, ~38 kDa) and 
Serp1 expression (red arrow, ~12 kDa). In this construction, it is obvio us that cpSRP43 co-expression vastly improves Serp1 expression from 
the Serp1 alone case. Expression is improved with both the L18 and the truncated L11 tag. However, overall Serp1 expression with L18 or 
L11 is similar between the 25˚C and 37˚C cases, as shown in the quantification. (b, right) Quantification of Serp1 expression. All values are 
normalized to the highest expression band, Serp1-L11+cpSRP43. Expression without cpSRP43 is negligible and there is little quantitative 
variation between expression at 25˚C versus 37˚C. 
 
Dependence of Membrane Protein Expression on L18-Tag. Because of the importance of the 
FDPLGL on the L18 region of LHCP for cpSRP43 aggregation prevention and disaggregation, we 
sought to study cpSRP43’s mechanism of action for non-native substrates by comparing substrates 
with the L18 motif, the L11 motif (a truncated version of L18 that includes the critical FDPLGL 
residues), and no L18 tag. We initially conducted this study in the vector in which cpSRP43 was 
FLAG-tagged and Serp1 was His-tagged and BL21DE3* cells were used for expression. This 
preliminary experiment shows a lack of L18 dependence. Under these conditions, Serp1 alone 
(Figure 11a, Lane 7) does not show any expression in the absence of cpSRP43 (see Supplemental 
Figure 3 for comparison of Serp1 alone expression for different cell types and tags). However, 
Serp1 that has been tagged with L18, L11, and no tag and co-expressed with cpSRP43 do not show 
significant differences in expression. Surprisingly, the construct with no tag appears to have 
somewhat higher expression than the L11 or L18 tagged version. Although this experiment must 
be repeated in the optimized conditions, this provides interesting clues as to how cpSRP43 is acting 
to improve membrane protein co-expression. For instance, it is possible that cpSRP43 is able to 
utilize hydrophobic interactions with Serp1 to prevent aggregation before it occurs, analogously to 





dependence under the optimized conditions. Although increased expression was shown with co-
expression of cpSRP43, differences in expression between L18, L11, and untagged substrates 
appear subtle. These L18 dependence experiments need to be repeated across the current pool of 
substrates to determine whether L18 dependence or lack of L18 dependence is a generalizable 
phenomenon. Such data will provide further insight into how cpSRP43 is able to improve 
expression of membrane protein substrates. 
(a)  (b)  
Figure 12. L18 dependence study using Serp1 (a) and Sec22 (b) as model substrates. The Serp1 study was performed using His-tagged 
substrate, FLAG-tagged cpSRP43, and BL21DE3* cells whereas the Sec22 study was performed with the optimized cpSRP43 conditions. 
Preliminarily these substrates do not show a large increase in expression with the L18 motif, indicating that perhaps these substrates do not 
form aggregates with as strong packing interactions as LHCP or cpSRP43 is able to make promiscuous hydrophobic contacts with these 
substrates before they are able to aggregate. 
 
Fractionation to Determine Cellular Location of Membrane Proteins During Co-
Expression. Although the co-expression data has shown some promise, it is important to 
determine whether the membrane proteins that are being expressed are forming inclusion bodies, 
being transported to the membrane, or interacting with cpSRP43 or other chaperones and 
remaining soluble. This question is important because it is known that membrane proteins that go 
into inclusion bodies can often not be in a functional form.18 To assess the distribution of 
membrane proteins between inclusion bodies, membrane, and soluble fractions, we used 
fractionation. Taking broken cells, we first pelleted them at 4000 g to remove any remaining 
unbroken cells. We then took the total fraction (that is, all of the broken cells) and centrifuged at 
16,000 g to remove inclusion bodies, which are heavy relative to other cellular components. 
Finally, we ultracentrifuged for 2 hours at 100,000 g to pellet the membranes. The remaining 
supernatant after this ultracentrifugation was labeled as the soluble fraction. Thus far, we have 
performed fractionation on Serp1 and Sec61B. We also performed fractionation on LHCP, which 
is known to be found only in inclusion bodies, as a control for the procedure. Fractionation was 
performed on Serp1 in both low expression cpSRP43 conditions (where cpSRP43 was FLAG-
tagged and Serp1 was His-tagged in BL21DE3* cells) and high expression cpSRP43 conditions 
from the final optimized conditions. 






Figure 13 shows the distribution of His6-tagged Serp1 co-expressed with FLAG-tagged cpSRP43 
in BL21DE3* cells. Under these pre-optimized conditions where cpSRP43 has low expression, 
Serp1 is distributed between the inclusion body, membrane, and soluble fractions with the highest 
fraction in the membrane and lower fractions in the inclusion body and soluble lanes. Low 
cpSRP43 expression is shown in the accompanying Coomassie-stained gel where cpSRP43 
appears to be predominantly in the soluble fraction. When Serp1 tagged with L11 was fractionated 
under these same pre-optimized, low cpSRP43 expressing conditions, it was found to be 
distributed between the inclusion body and the membrane with very little detectable in the soluble 
fraction (Figure 14). LHCP was used as a control to confirm the fractionation method. LHCP is 
known to be found in inclusion bodies, and these fractionation results, which show LHCP only in 
the inclusion body fraction and not in the membrane or soluble fractions, confirm that the inclusion 
bodies are being successfully separated from membrane and soluble fractions. 
(a) (b)  
Figure 13. Fractionation of Serp1 tagged with L18 and co-expressed with cpSRP43 under pre-optimized conditions (low cpSRP43 
expression).  (a) anti-His western blot for Serp1 fractionation. Serp1 is distributed between the fractions with the highest amount in the 
membrane fraction. (b) Coomassie-stained gel showing cpSRP43 fractionation. cpSRP43 has very little in the membrane, slightly more in the 






Figure 14. Anti-His western blot of the fractionation of Serp1 (with pre-optimized, low expressing cpSRP43 conditions) and LHCP. Serp1 is 
tagged with L11 and is co-expressed with cpSRP43. LHCP, which is known to be found in inclusion bodies, is expressed as a control. 
IB=Inclusion body, M=Membrane, S=Soluble.  
 
These fractionation experiments were repeated for Serp1 and Sec61B in the optimized conditions 
(His-tagged cpSRP43, FLAG-tagged substrate, BL21-CodonPlus-DE3-RIL cells). Serp1 
fractionation with and without cpSRP43 co-expression is shown in Figure 15. In the cpSRP43-
Serp1 co-expression case, Serp1 is mainly found at the expected molecular weight of 12 kDa with 
the largest portion in the membrane fraction, some in the inclusion body fraction and little in the 
soluble fraction. In the Serp1 alone case most of Serp1 is found in the inclusion body fraction with 
little in the membrane or soluble fractions (note that there is some non-specific exposure on the far 
right side of the Serp1 alone western blot). Moreover, the Serp1 alone case shows many more 
higher molecular weight species (potentially oligomers) that could correspond to non-functional 
Serp1. cpSRP43 may therefore be able to keep Serp1 and other membrane proteins in a functional 
form by helping them to get to the membrane rather than allowing them to aggregate in inclusion 
bodies. This hypothesis must be further tested across a variety of substrates to more fully 
understand whether cpSRP43 is able to increase expression of functional membrane proteins by 






Figure 15. Anti-FLAG western blot of Serp1 fractionation. In the cpSRP43 co-expression case (left) the greatest fraction is found in the 
membrane at the expected 12 kDa molecular weight. By contrast, the Serp1 without cpSRP43 case (right) shows the largest fraction in the 
inclusion body and moreover this case shows many higher molecular weight bands, potentially indicating oligomerization of Serp1 in the 
inclusion body. 
 
Sec61B Fractionation. Fractionation was also performed with Sec61B co-expressed with 
cpSRP43 under the optimized cpSRP43 expression conditions. In this fractionation, cpSRP43 
was found to be distributed in the inclusion body, membrane, and soluble fractions, with the 
highest fraction in the soluble portion (Figure 16). An anit-FLAG western blot indicated that 
much of Sec61B was found in the membrane fraction and soluble fraction and little was found in 
the inclusion body (Figure 17). Although the high proportion in the membrane fraction is 
promising (approximately 40% by quantification) the similar amount in the soluble fraction is 
intriguing. It is possible that cpSRP43 is interacting with Sec61B, keeping it soluble. However, it 
is unclear what effect this will have on the functionality of the protein. This experiment must be 
repeated in both with and without cpSRP43 conditions in order to assess whether cpSRP43 co-







Figure 16. Coomassie-stained gel of fractionation of cpSRP43 co-expressed with Sec61B (left) and quantification of fractions (right). The 
greatest fraction is found in the soluble portion with smaller amounts found in the inclusion body and membrane fraction. 
 
Figure 17. Anti-FLAG western blot of Sec61B co-expressed with cpSRP43 (left) and quantification of the fractions (right). Sec61B is found 











To summarize, we have tested the usefulness of cpSRP43 co-expression for improving membrane 
protein expression across a preliminary range of substrates including Serp1, Sec61B, MscL27, 
Cyb5, Sec22, Scs2, Bos1, and Use1. The most promising substrates thus far are Serp1, Sec61B, 
Sec22, Scs2, and Use1. Further we have assessed the necessity of the L18 motif for improving 
membrane protein co-expression and these initial results have indicated that this motif may not be 
necessary for some substrates, which could be promising as these substrates could potentially be 
purified without, for example, needing to have the L18 tag cleaved. To test for the localization of 
the expressed membrane proteins in the cell, we used fractionation and found that most cpSRP43 is 
found in the soluble fraction, as expected, and that a high proportion of Serp1 and Sec61B is found 
in the membrane fraction when co-expressed with cpSRP43. Our future work will include 
expanding our membrane protein substrate scope to further probe the usefulness of cpSRP43 co-
expression. We will also determine the L18 dependence of our current and future substrates by 
making L18, L11, and deltaL18 versions of all substrates. Moreover, we will test the importance of 
the location of the L18 tag within the substrate. In the native LHCP substrate, the L18 tag is placed 
between TM2 and TM3. For multiple TM substrates such as MscL27 we will try placing the L18 
tag in between its two TM’s to assess whether this can increase expression. In tail-anchored 
substrates we have put the L18 tag on the C-terminus but we can likewise try putting the L18 tag 
on the N-terminus to determine if this is able to increase expression. By varying the location of the 
L18 tag and potentially obtaining substrates with more TMs, we can more fully assess the 
importance of the L18 tag in cpSRP43 chaperone activity of non-native substrates. 
 
These cpSRP43 co-expression experiments have shown promise for cpSRP43 as a potential tool 
for increasing membrane protein expression. Because membrane proteins are found commonly in 
biological systems but are often not characterized due to their poor expression, developing tools for 
improving membrane protein expression is an important objective. Further, studying cpSRP43 co-
expression can provide another approach for understanding cpSRP43 activity and mechanism for 
non-native substrates through L18 dependence studies and further through assessing whether 
cpSRP43 is able to deposit substrates on the membrane through fractionation. Although these 
experimental results provide a promising start for cpSRP43 as a tool for understanding and 
overcoming problems of protein aggregation, more work must be done to understand how 
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A result of switching from FLAG-cpSRP43 and His6-substrate in BL21DE3* cells to His6-
cpSRP43 and FLAG-substrate in BL21-CodonPlus-DE3-RIL was seeing baseline expression of 
Serp1 without cpSRP43 increase. This change in Serp1 alone expression with tag and cell type is 
shown in Supplementary Figure 1. 
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Carbon-carbon (C-C) bonds are fundamental components of a wide variety of industrial molecules 
including pharmaceuticals, fuel, and agricultural products; methods for forming C-C bonds are 
thus critical to industrial production. However, industrial syntheses often rely upon large quantities 
of toxic reagents and extreme conditions such as high temperature and pressure. Biologically-
derived catalysts, which often function in aqueous and ambient conditions, have emerged as a 
powerful tool to help make industry more green and open up novel synthetic pathways. Here we 
use nitrogenase and a representative substrate, methyl isonitrile, to study a mechanistically 
uncharacterized C-C bond formation reaction. Nitrogenase is a two component metalloenzyme that 
catalyzes biological nitrogen fixation, the reduction of atmospheric nitrogen (N2) to bioavailable 
ammonia (NH3). Moreover, nitrogenase is capable of catalyzing other useful chemistries such as 
reducing methyl isonitrile to form methane, methylamine and intriguingly also ethane, ethylene, 
and higher hydrocarbons. We utilized an interdisciplinary kinetics-based approach to characterize 
the C-C bond formation mechanism between methyl isonitrile and nitrogenase. This work will 
serve not only as an important characterization of an applicable synthetic tool, but also as a 









Nitrogenase is the only known family of enzymes capable of biological nitrogen fixation, or the 
ATP-powered conversion of atmospheric nitrogen (N2) to bioavailable ammonia (NH3) (Figure 1). 
Nitrogen fixation is critical for making soil fertile, and as such nitrogenases are commonly found in 
microorganisms such as Azotobacter vinelandii and Clostridium pasteurianum. Significantly, this 
biocatalyzed process serves as an alternative to the Haber-Bosch process, a widely used nitrogen 
fixation method which requires conditions of high temperature and pressure.1 Nitrogenase has long 
served as a system of interest to help green the industrial production of ammonia; here we seek to 
build upon this work by studying another important chemistry catalyzed by nitrogenase, carbon-
carbon (C-C) bond formation.  
 
 
Background and Significance 
 
Although the complete mechanism of nitrogenase remains elusive, a variety of biophysical 
characterizations have provided key insights into the components of this complex biological 
system.2-7 Nitrogenase is composed of two metalloprotein components: the iron (Fe) protein (called 
Av2 when purified from soil bacteria Azotobacter vinelandii) and the molybdenum-iron (MoFe) 
protein (Av1). Dinitrogen reduction is an ATP-dependent process initiated by electron transfer 
from the [4Fe:4S]-cluster of the Fe-protein to the MoFe-protein, which contains P-cluster [8Fe:7S] 
and FeMo-cofactor [7Fe:9S:C:Mo] metal centers.2 These proteins and electron transfer reactions 
are described in Figure 2,8,9 namely ATP-consumption drives electron transfer from the [4Fe:4S]-
cluster to the P-cluster to the FeMo-cofactor.  
Recent studies from the Rees Group have generated CO- and Se- bound forms of the 
cofactor generated under turnover conditions, providing further insight into the potential binding 
mechanism of substrates and inhibitors to the FeMo-cofactor.4,7 The FeMo-cofactor is composed of 
a trigonal prism containing an interstitial carbide that is thought to stabilize the cofactor during 
rearrangements associated with substrate binding. Substrates bind only to the more highly reduced 
forms of the enzyme that are efficiently generated only with the Fe-protein and ATP consumption. 
These studies provide an excellent starting point to assess whether the structure containing methyl 
isonitrile bound to nitrogenase undergoing C-C bound formation, matches with the prediction from 
the two CO bound structure that this “high-CO” form may represent an intermediate relevant to the 
carbon-carbon (C-C) coupling reaction.10   
Nitrogenase is a powerful enzyme capable of performing various reduction chemistries 
including the conversion of methyl isonitrile to methane and methylamine. Interestingly, additional 
products of nitrogenase-methyl isonitrile interactions include ethane, ethylene, and higher 
hydrocarbons, indicating that nitrogenase is capable of not only reduction but also C-C bond 
formation.11-15 Understanding this mechanism could have significant applications for biocatalyzed 










We can organize this research endeavor into a few key biochemical questions: 1.What does 
the intermediate in ethane formation from methyl isonitrile look like while interacting with 
nitrogenase? 2.What are the kinetics of two carbon product formation from this interaction? 3.Will 
crystallizing methyl isonitrile in complex with nitrogenase provide insight into this mechanism?  
To address these key research questions we have the following specific aims: Aim 1.) Form 
a complex between methyl isonitrile and nitrogenase under turnover conditions. Aim 2.) Perform 
gas chromatography under various conditions to study the mechanism and kinetics of this carbon-
carbon bond formation. Aim 3.) Crystallize complex through optimization of crystallization 





Our experimental approach involves an interdisciplinary series of experiments to extract 
useful organic tools from a biological system. The bacterial species Azotobacter vinelandii will be 
grown in a fermenter, and Av1 and Av2 will be purified from this cell lysate anaerobically using 
specialized tent and Schlenk line environments. Acetylene will be used as a standard substrate to 
confirm the activity of the Av1/Av2 complex via gas chromatography. Methyl isonitrile synthesis 
will be performed under vacuum as described in Organic Synthesis11,12 and visualized in Figure 4. 
Gas chromatography using various concentrations of methyl isonitrile and nitrogenase components 
will be performed to quantify kinetics of product formation. Ultimately, methyl isonitrile in 
complex with nitrogenase will be generated under turnover conditions4 and subsequently 
crystallized to directly study C-C bond formation. Solving the structure of this complex will 







Experimental Approach Figures 
 
Figure 1. Nitrogen fixation performed by metallloenzyme nitrogenase. In this 
nitrogenase, dinitrogen is converted to ammonia through series of electron 
transfer reactions powered by ATP hydrolysis.2 
 
 
Figure 2. (left) Nitrogenase electron 
flow through Fe (composed of 
homodimeric gamma subunits in 
purple and blue)16 and MoFe proteins 
(composed of alpha subunits in blue 
and beta subunits in green)17 via 4Fe-
4S cluster in Fe protein to P-cluster 





Figure 3. (above) Methyl isonitrile 
forms one and two carbon products in 
the presence of nitrogenase. 
 
 








To begin this project, we first purified nitrogenase anaerobically (Figure 5). A fermenter was used 
to grow Azotobacter vinelandii (Av) which were then broken with an Emulsfilex and the resulting 
cell lysate was used to obtain Av1 (MoFe) and Av2 (Fe) from an ion exchange column (separating 
Av1 and Av2) followed by a size exclusion column for each protein. Purification was performed 




Figure 5. Purification of nitrogenase followed by gas chromatography and crystallization with methyl isonitrile. 
 
Methyl isonitrile was purchased from the abcd company (a German chemical company). With 
nitrogenase and methyl isonitrile in hand, we first sought to reproduce observation of C-C bond 
formation via gas chromatography.  
 
Our first task was to use gas chromatography and PeakSimple software to optimize for C-C bond 
formation conditions. These reactions are known as activity assays as they are a measure of 
nitrogenase activity for a given substrate (Figure 6). Performing an activity requires turnover 
conditions, also referred to as an ATP regeneration system such a setup requires MgCl2, ATP, 





performed with these conditions under Argon in the presence of dithionate, nitrogenase, and 
substrate of interest, in this case methyl isonitrile. 
 
Figure 6. Anaerobic setup (left), activity assay conditions (center), and activity assay procedure (right) for 
monitoring nitrogenase activity. 
 
 
We first tested the activity of the purified nitrogenase using a standard acetylene reduction assay 
(Figure 7) and found that the activity fell on the low side of the expected range (usually ~2000 
nmol ethylene/min/mg Av1), meaning we could then go on to use this batch of nitrogenase with 










As expected,15 when methyl isonitrile is incubated with nitrogenase it is reduced to methane 
(Figure 8). Methane formation peaks around 2.5 mM MeCN and becomes inhibited after this 
concentration as MeCN can act as both a substrate and an inhibitor. 
 
Figure 8. Methyl isonitrile is reduced to methane in the presence of nitrogenase. 
 
When methyl isonitrile is incubated with nitrogenase it also forms ethane and ethylene (Figure 9). 
C2 bond formation appears to peak around 5mM methyl isonitrile. These results are similar to 
those found in the literature for C2 bond formation under methyl isocyanide titration 
conditions.13,14 To further understand this C-C bond formation chemistry, we will attempt to 






Figure 9. Methyl isonitrile forms C-C bonds in the presence of nitrogenase. Peak bond formation appears at 
about 5 mM methyl isonitrile. 
 
Following the methyl isonitrile titration, favorable conditions for C2 bond formation were found at 
CR 10 and pH 7.5. Through this project we found optimized conditions for C2 production, namely 
a component ratio of 10, pH 7.5, [MeCN] = 5.0 mM. With these conditions in hand we sought to 
use crystallization to study the structure of nitrogenase interacting with methyl isonitrile. Although 
these conditions did not yield crystals, the optimization of C2 product formation is still very 
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To compliment nitrogenase experimental work on methyl isonitrile I performed a literature review 
on nitrogenase substrates. Nitrogenase is capable of handling a wide variety of substrates, which I 
have organized here in a substrate table. This review shows the breadth of reactions nitrogenase is 
capable of catalyzing. Further, I go on to assess the role of hydrazine in nitrogenase mechanism 







Understanding the nitrogenase substrate scope is valuable for further understanding the enzyme 
itself. In this review I identify various substrates through the literature and compile a thorough list 
of these substrates. Among this substrate scope is hydrazine, a potential intermediate in dinitrogen 
reduction. I explore the evidence for and against hydrazine as an intermediate in this enzymatic 
reaction. 
Table of Nitrogenase Substrates 
This table represents a literature survey of know substrates and inhibitors of nitrogenase presented 
with relevant binding information and sources. 
Table 1. Table of nitrogenase substrates demonstrating the variety of structures nitrogenase is capable of 
accommodating. 
Substrate Product(s) KM 
H+ H2  
N2 2NH3 0.1-0.2 atm 
N2H4 2NH3 (2e-) 20-30 mM 




N2O N2 (2e-) 1 mM 
NO2- NH3 (6e-)  
C2H2 C2H4 
cis C2H2D2 
0.003 – 0.02 atm 
C2H4 no reduction?  
CH3C=CH CH3CHCH2 0.5 atm 
C2H5C=CH C2H5CHCH2 too large to measure 











cyclopropene cyclopropane (2e-) 
cis D2 cyclopropane 
CH3C=CH (2e-) 
0.012 atm 
N=CNH2   







HCN (CN-?) CH3NH2 (4e-) 
CH4+NH3 (8e-) 
CH2NH (2e-) 
4.5 mM HCN 
CH3CN C2H6+NH3 (6e-) 500-100 mM 
C2H5CN C3H8+NH3 (6e-)  
C3H7CN C4H10+NH3 (6e-)  
(CH3)2CHCN  not a substrate 
CH3NC CH3NHCH3 (4e-) 
CH2NH2+CH4 (6e-) 
0.7 mM 
C2H5NC   
H2C=CHNC C3H6+NH3 (6e-) 
C3H8 + NH3 (8e-) 
(0.8 mM)? 10-50 mM 
H2 inhibitor  
CO inhibitor  
NO inhibitor  
CH2N2   
CO2   
CS2  1.7 mM 
COS   
CH3C6H4C=CH CH3C6H4C=CH  
HC=C-CH2OH HC=C-CH2OH  
NH2OH NH3 30 mM 
HC=CCH2N2 HC=CCH2N2  
H2C=CCH2OH H2C=CHCH2OH (alpha-70Ala) 
HN=NCH3 HN=NCH3  
HN=NH NH3 4.5 mM 
HN=NCH3 inhibitor  
H+ HD  
N=CS- HCN+H2S, (2e-) 
CH4+NH3(6e-) 
0.9 mM 
OCN- CO+H2S (2e-) 6.1 mM (pH 6.0) 
20 mM (pH 6.5) 
Trans-dimethyldiazerene   
HC=CCHOH HC=CCHOH  
HC=CCH2NH2 HC=CCH2NH2  
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The metalloenzyme nitrogenase catalyzes the conversion of dinitrogen to ammonia. The 
mechanism of nitrogenase’s conversion of dinitrogen to ammonia remains unclear despite decades 
of research. Here we will review evidence for and against hydrazine as an intermediate in this 








Nitrogenase is a metalloenzyme from soil bacteria that catalyzes the conversion of dintrogen (N2) 
to bioavailable ammonia as shown in the below equation1: 
𝑁! + 8𝑒! + 16𝑀𝑔𝐴𝑇𝑃 + 8𝐻! → 2𝑁𝐻! + 𝐻! + 16𝑀𝑔𝐴𝐷𝑃 + 16𝑃! 
 Nitrogenase is composed of two component proteins, the MoFe protein (also known as Av1 in 
Azotobacter vinelandii) and the Fe protein (or Av2) which work together to carry out dinitrogen 
reduction. MoFe protein contains the binding site for substrates composed of a 9S-Mo-X-
homocitrate cofactor (FeMo-cofactor). MoFe also contains the P-cluster [8Fe-7S] which mediates 
electron transfer from the Fe protein. The Fe proton transfers electrons to MoFe coupled with 
stoichiometry of 1e-/2 ATP.  
Although this enzyme has been extensively studied, its mechanism remains elusive. One 
possibility is a Chatt-type mechanism or alternating pathway mechanism in which nitrogenase is 
first converted to diazene which goes through a hydrazido state to arrive at hydrazine that is then 
converted to ammonia. An alternative mechanism, called the distal pathway, involves going 
through a diazenido state, releasing one ammonium to a nitrido state then to an imido state and 
finally the second ammonium. In this review we will assess evidence for and against hydrazine as 




There are five general arguments that support hydrazine as an intermediate: 1) hydrazine can act as 
a substrate of nitrogenase,1–9 2) hydrazine can be detected when nitrogenase is acid-quenched,10 3) 





ammonia can be catalyzed by various nitrogenase-like synthetic catalysts,16–20 and 5) hydrazine can 
be observed as an intermediate via EPR.8,9 These possibilities are summarized in the table below 
with their respective sources. 
Table 2. Arguments for and against hydrazine as an intermediate with the respective sources. 
For Hydrazine Intermediate Against Hydrazine Intermediate Source 
1) Hydrazine acts as a substrate to 
nitrogenase 
Low reactivity in WT nitrogenase; 




2) Hydrazine appears when nitrogenase is 
acid quenched 
Could be an artifact of the presence of 
acid 
10 
3) Hydrazine is released by V-nitrogenase 
during N2 reduction as a minor product; 
formation of small amounts of hydrazine 
during catalytic activity 
Doesn’t necessarily mean Mo-
nitrogenase follows same mechanism; 
isn’t necessarily on pathway to NH3 
11-15 
4) Hydrazine to ammonia can be catalyzed 
by MFe3S4 catalysts, various nitrogenase 
metal catalytic mimics, molybdenum 
thiolate complexes, and mononuclear 
MCP*Me3 cores. 
How physiologically relevant to 
nitrogenase are these catalysts 
16-21 
 
1) Although these evidences support hydrazine as an intermediate for biological nitrogen fixation, 
there is also significant evidence against this intermediate. Although hydrazine can act as a 
substrate of nitrogenase, it is a very poor substrate in WT nitrogenase. To study hydrazine as a 
substrate, mutant forms of nitrogenase were made. To accommodate hydrazine, nitrogenase was 
mutated to α-70Ala/α-195Gln, hydrazine was used as a substrate, and this complex was freeze 
trapped and monitored by EPR.1 Additionally 15N2H4 was used with pulsed ENDOR to confirm 
that the intermediate observed by EPR was derived from hydrazine. In another work studying 
hydrazine as a substrate, it was found that when Fe protein is substituted with an EII-DPTA system 
and a β-98His mutant of MoFe is made, hydrazine is reduced to ammonia but N2 is not reduced.4 





the same in the WT nitrogenase system. In the absence of mutations, hydrazine is a poor substrate 
for WT nitrogenase, constituting only about 10% of electron flow compared to protons. Further, 
hydrazine can act as a noncompetitive inhibitor of acetylene reduction. Changing α-70Val to alanine 
greatly improves hydrazine reduction, as previously obsserved.9 When α-70Val is substituted with 
isoleucine, hydrazine reduction is eliminated.  Lukoyanov et al. used cryoannealing to trap a 
diazene (2N2H) species and monitor it via EPR.8 Hydrazine could then act as an intermediate after 
decay of this species. Thus Lukoyanov et al. do not specifically observe hydrazine as an 
intermediate but rather a diazene-level intermediate that could be on pathway to a hydrazine 
intermediate. Although hydrazine has been observed by EPR in the nitrogenase system this may 
not be an on pathway intermediate but rather an artifact of reaction conditions since WT 
nitrogenase is very unreactive with hydrazine. Overall it is unclear whether mutants that interact 
with hydrazine are relevant to WT nitrogenase and thus whether hydrazine acts as a substrate in the 
native nitrogenase remains unclear. It is possible that if hydrazine acts as an intermediate, these 
mutations mimic conditions for hydrazine already having access to active site upon reduction from 
dinitrogen. 
 
2) The second argument involves seeing hydrazine upon acid or alkali quench. Although hydrazine 
could be a captured intermediate, it is also possible that acid or base produces hydrazine and that 
hydrazine would not be there otherwise. That is, it is possible another nitrogenous intermediate 
underwent maturation under these conditions to yield the observed hydrazine. Again, in straying 
from physiological conditions it is challenging to determine whether or not this evidence is 





in solution, suggesting that if this species is relevant it is as an intermediate within nitrogenase and 
not as a free species. 
 
3) It was found by Dilworth et al. that vanadium-based enzyme develops around 0.5% N2H2 per 
converted N2 during catalytic turnover.13 Thus in the Vanadium nitrogenase it appears that 
hydrazine is a product in V-nitrogenase dinitrogen reduction. Hydrazine is found to be free in 
solution and not enzyme-bound under these conditions and this suggests that hydrazine is a product 
for VFe and not a bound intermediate, in contrast to the Thorneley et al. quenching case. This does 
provide evidence for a four-electron reduced dinitrogen hydride species on V-nitrogenase capable 
of dissociating hydrazine.13 Further, more hydrazine is produced from the vanadium nitrogenase 
with increasing temperature.12 However, this doesn’t necessarily mean that the molybdenum 
nitrogenase has the same mechanism and thus the same intermediate. Hydrazine has not been 
observed for the molybdenum nitrogenase as it has been for the Vanadium nitrogenase so this may 
represent a divergence between the two systems. Although V-nitrogenase and Mo-nitrogenase are 
similar in structure and function, V-nitrogenase evolves more H2 during N2 reduction. 
 
4) Crossland et al. show 𝜂2 coordination of hydrazine to iron in a small molecule comples, which 
may mimic nitrogenase intermediates during turnover.16 Coucouvanis et al. demonstrate the 
reduction of hydrazine to ammonia using MFe3S4 clusters (M=Mo, V) demonstrating that 
nitrogenase could possibly perform similar hydrazine reduction chemistry. Although hydrazine can 
be transformed to ammonia by small molecule clusters, this again isn’t for certain evidence that 





which demonstrates that hydrazine can be converted to ammonia but it is unclear whether this 
happens in the physiological case. 
Rittle et al. show that N2 can be converted to hydrazine and then to ammonia on a Fe catalyst via 
Fe=NNH2, thus demonstrating a hybrid distal to alternating pathway for N2 reduction. This 
indicates that hydrazine can appear in the reduction pathway even if its not a purely alternating 
model which opens the possibility of hydrazine acting as an intermediate in a variety of models. 
Again, although this is observed through synthetic catalysis it is uncertain how well this 
physiologically mimics nitrogenase. Further, hydrazine was observed after acid quenching and it is 




Overall, there is strong evidence to support hydrazine as an intermediate in N2 reduction to 
ammonia by nitrogenase. Hydrazine can act as a substrate, though it is a weak substrate of WT 
nitrogenase and works better with mutated forms of the enzyme.1 Further, hydrazine has been 
observed upon acid quenching of nitrogenase indicating that it is a potential intermediate in N2 to 
NH3 reduction.10 However, despite this evidence it is not certain whether hydrazine in on pathway 
to N2 reduction as a hydrazine intermediate has not been directly detected as a product important in 
N2 reduction. Its poor reactivity as a substrate for WT nitrogenase indicates that it may not be an on 
pathway intermediate; similarly the need to mutate nitrogenase to accommodate hydrazine to 
observe this intermediate also indicates the alternating mechanism may not necessarily be 
physiological. Further, acid quenching could cause the production of hydrazine which may not be 
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C o n c l u s i o n  
OF CHAPERONES AND ENZYMES 
Biological tools are useful case studies for organic chemists, biochemists, and beyond. My 
results from cpSRP43 and nitrogenase demonstrate that we should keep learning from 
biological systems to create pharmaceuticals and other industrial products. 
Through studying cpSRP43 we demonstrated the interaction of cpSRP43 with its substrate, LHCP, 
and characterized this interaction surface to be the TM’s, loop 1, and L18, from the point of view 
of the substrate and the beta-sheets, bridging helix, and Y204 from the point of view of the 
chaperone. Further we showed how cpSRP43 uses effectors to be finely spatially and temporally 
controlled. cpSRP43 was biophysically characterized to undergo an unfolded-folded transition 
upon binding substrate and cpSRP54M. cpSRP43 was then used as a tool to increase membrane 
protein expression. cpSRP43 can also potentially be used as a tool to prevent the aggregation of 
amyloid-beta found in Alzheimer’s and other such disease-related aggregation-prone proteins. 
cpSRP43 is thus a well, characterized tool with great engineering potential to tackle protein 
aggregates in human disease. 
In studying nitrogenase, I optimized conditions for C-C bond formation with methyl isonitrile. 
These conditions were then used to setup crystal trays to study the structure of this complex. 
Further, I studied the substrate scope of nitrogenase and the role of hydrazine in the nitrogen 
fixation pathway. 
Overall, these works serve as fascinating case studies into using existing biological machinery for 
useful medical and industrial applications. 
 
 
 
  
 
